curriculum vitae prof. rifaat safadi m.d....4 prof. rifaat safadi m.d., february 12th, 2017 4 prizes...

1 Prof. Rifaat Safadi M.D., February 12th

, 2017

1

CURRICULUM VITAE

Prof. Rifaat Safadi M.D.

1. Personal Details:

Date of Birth: 24/01/1965

Country of Birth: Nazareth, Israel.

Date of Immigration: NA

ID no.: 59367979

Nationality: Israeli Arab

*Marital status: Married to Sana

*No. of children: a father for 3 children

Permanent address: Nitufa St. #3, POB 4825, Nazareth Elit 17501, Israel.

Home Tel.: +972 4 6011696

Work Tel: +972 2 6777337, Fax +972 2 6420338

Cell: +972 50 8573574

E-mail address: [email protected]; [email protected]

Director for the Liver Unit, Institute of Gastroenterology and Liver Diseases, Division

of Medicine, Hadassah, Ein-Karem POB 12000, 91120 Jerusalem, Israel

License numbers: Medicine: 21947

Internal Medicine: 14123

Gastroenterology: 16059

2. Higher Education:

2009-2010: Administrations Course for Departments & Clinics, Uno College.

2001-2002: Visiting Scholar, Division of Liver Diseases, Mount Sinai School of

Medicine, New York/NY. Host: Prof. Scott Friedman.

1995-1997: Residency in Gastroenterology, Hadassah University Hospital, Jerusalem

1991-1995: Residency in Internal Medicine, the Division of Medicine, Hadassah

University Hospital, Jerusalem

1990-1991: Internship, Hadassah University Hospital, Jerusalem

1986-1989: MD. Faculty of Medicine, Hadassah Hebrew University of Jerusalem.

1983-1986: B.Sc. Health Science. Faculty of Medicine, Hebrew University,

Jerusalem

mailto:[email protected]

mailto:[email protected]


, 2017

2

3. Appointments at the Hebrew University:

2011 - Present: Professor in Medicine, Faculty of Medicine, Hadassah University

Hospital, Hebrew University, Jerusalem

22/1/06 - 2011: Senior Lecturer in Medicine, Faculty of Medicine, Hadassah

University Hospital, Hebrew University, Jerusalem

1/3/02 - 21/1/06: Clinical Senior Lecturer in Medicine, Faculty of Medicine, Hadassah

University Hospital, Hebrew University, Jerusalem

1995 - 28/2/02: Lecturer in Medicine, Faculty of Medicine, Hadassah University

Hospital, Hebrew University, Jerusalem

1993 - 1995: Clinical Instructor in Internal Medicine, Faculty of Medicine,

Hadassah University Hospital, Hebrew University, Jerusalem

4a. Additional Functions/Tasks at the Hebrew University:

Since 2013: Profissional Committee member for “Promotions”

Since 2013: A Committee member for “Excellence”

Since 2010: Education Committee member for “Promotions”

Since 2009: A member for “The Student Exchange & Continuing Education”

Since 2009: Committee member for “The committee of teaching skills evaluation”

2005-2007: Scientific Committee member for “Promotion committee for Lecturers”

2003-2009: Coordinator of the “Problem Based Learning”

1998-2001: Reviewer Board, Internal Medicine exams for graduate medical students

Since 1997: Interviewer of candidates for studying Medicine

Since 1996: Examiner, Board of Internal Medicine

4b. Additional Functions/Tasks at the Hadassah Hospital:

Since 2011 Director for the Liver Unit, Institute of Gastroenterology and Liver

Diseases, Division of Medicine, Hadassah, Ein-Karem

2009 - 2010: A member of “Strategic Planning Committee for Education in the Health

Professions”

2004 - 2006: Committee member, “Developing Somatic Cell Transplantation Center”

Since 1994: Senior physician, Liver Unit, Gastroenterology & Division of Medicine

1994 - 1997: Treasurer in the Hadassah Physician Board.


, 2017

3

5. Service in other Academic and Research Institutions:

2013-2017: Consultant for the Israeli Health Basket, Ministry of Health.

2013-2016: Chairman, Israel Association for the Study of the Liver.

2009-2012: A member of the Public Information Committee of The European

Association for the Study of the Liver (EASL), Geneva.

2009-2011: A member of the International Relations Advisory Committee of AASLD

(American Association for the Study of Liver Diseases).

2009-2011: Consultant to Nazareth Hospitals in affiliation processing for the new

Gallillee Medical School & establishing of Nazareth research laboratory.

2007-2010: Scientific Committee & Governing Board member, The European

Association for the Study of the Liver (EASL), Geneva.

2003-2006: Governing Board member, The Israeli Association for the Study of Liver.

2003-2006: Treasurer: The Israeli Association for the Study of Liver.

2003-2006: Treasurer, the Israeli Association for the Study of Liver

2003-2006: Committee member, the Israeli Association for the Study of Liver

2001-2002: Fellowship, Division of Liver Diseases, Mount Sinai School of

Medicine, New York/ New York.

Since 1998: Director Liver Unit, Holy Family Hospital, POB 8, 16100 Nazareth,

Israel, Tel/Fax 972-4-6508900/22

6. Other Activities:

Membership in editorial boards of academic journals:

Since 2015: Editor in-chief for the "Journal of Targeting Liver Diseases"

Since 2014: Editorial Board of Liver International (IF=4.47)

Since 2012: Academic Editor for "PLOS ONE" (IF=3.73)

2011-2014: Member of Editorial Board for “Journal of Hepatology” (IF=10.041)

2009-2014: Journal Editorial Adviser for “Clinical Science” (Impact Factor 5.629)

2009-2-13: A member of the Editorial Board of World Journal of Hepatology (WJH)

2007-2010: Editorial Administrator of the “Journal of Hepatology” as an EASL

Governing Board & Scientific committee member:

Selection of the new Chief Editor & Editorial Board, 2009

Opening main EASL & Journal of Hepatology office, Geneva, 2009


, 2017

4

Prizes awarded:

2012: Presidential Plenary Oral Presentation, the “American Association for the

Study of Liver Diseases” 2012 annual meeting. Topic: “Vitamin D levels

in Nonalcoholic Fatty Liver Disease associate with Insulin resistance and

Liver progression via a Novel NLG4 dependent NK recognition”. (Johnny

Amer won the AASLD Yound Investigatos Travel Award).

2010: Presidential Poster, the “American Association for the Study of Liver

Diseases” 2010 annual meeting. Topic: “Lymphocytes attenuate fibrogenic

toxicity of bile acids; using in-vitro and in-vivo Parabiosis mice system”.

2010: Presidential Poster, the “The Isreali Association for Gastroenterology &

Hepatology” 2010 annual meeting. Topic: “Pivotal effects of Toll-like

receptor-9 activation in hepatic fibrosis”, manuscript#10.

2009: Presidential Poster, the “The Isreali Association for Gastroenterology &

Hepatology” 2009 annual meeting. Topic: “The pivotal role of hepatic

stellate cells in hepatocellular carcinoma progression” , manuscript#8.

2009: Presidential Poster, the “American Association for the Study of Liver

Diseases” 2009 annual meeting. Topic: “CB2 cannabinoid receptors

directly affect hepatic stellate cell activation with lymphocyte alterations”,

manuscript#13.

2006-2007: Excellent Hadassah Scientist Award, Approved on 10/12/2006. “siRNA for

the immune modulation of fibrosis”, $11,000, Original Papers in Peer

Reviewed Journals, manuscript#23.

2003-2004: Return to Hadassah Award, “Immune Modulation of Hepatic Fibrosis”,

92,000/92,000 NIS, Original Papers in Peer Reviewed Journals,

manuscript#25, 27, 28, 31-34.

2002 Sharon Donsky Award, “Immune Modulation of Fibrosis Associated

Hepatoma”, $3000/$3000, Original Papers in Peer Reviewed Journals,

manuscript#31-34.

2001-2002: American Physician Fellowship Award, “Immune Modulation of Hepatic

Fibrosis”, $5000/$5000, Original Papers in Peer Reviewed Journals.

Manuscript#11-14, #16 & #24.

2001-2002: Israeli Gastroenterology and Hepatology Association Award, “Immune

Modulation of Hepatic Fibrosis”, $1000/$1000, Original Papers in Peer

Reviewed Journals. Manuscript#25, 27, 28.


, 2017

5

Organizing conferences:

Organizer and Chair of the upcoming The International Conference on Fatty Liver,

Seville, Spain June 1-3, 2017

Organizer and Chair of the upcoming Drug development Symposia, with HADASIT,

Hadassah 7/2/2017

Fatty Liver Disease. The Annual Liver Meeting. The Israel Association for the Study

of Liver. Tel Aviv, November 2016

General Hepatology. The Annual Liver Meeting. The Israel Association for the

Study of Liver. Eilat, June 2016

HCC: Screening, Imaging & Therapy. The Israel Association for the Study of Liver,

Tel Aviv, 29/3/2016

Viral Hepatitis eradication & Beyond. The Israel Association for the Study of Liver,

Tel Aviv, 13/10/2015

Second World Conference on Targeting Liver Diseases, Clinical Innovations &

Biotechnology. Jerusalem: June; 25-26, 2014. Co Chaired with the International

Society for Anti Oxidants Heath & Nitrition. Malta

Liver Inflammation. The Annual Liver Meeting. The Israel Association for the Study

of Liver. Eilat, June 2015

Updating Guidelines in Hepatology. The Israel Association for the Study of Liver,

Zechron Yaakov, 17/2/2015

Viral Hepatitis & Addiction. The Israel Association for the Study of Liver, Tel Aviv,

29/10/2014

First World Conference on Targeting Liver Diseases, Clinical Innovations &

Biotechnology. Jerusalem: June; 26-27, 2014. Co Chaired with the International

Society for Anti Oxidants Heath & Nitrition. Endorsed By The Israel Association for

the Study of Liver, European Association for the Study of Liver and Hadassah

Medical Center. Jerusalem, Israel

Hepatobiliary Conference in Memeory of Yossi Shladov, 22/5/2014, Dan Acadia,

Hertzlia. Co Chaired with the Israel Sosciety of Imaging.

The Annual Liver Meeting. The Israel Association for the Study of Liver. Eilat June

2014

The fifth HIV-HCV-HBV Coinfection Conference. The Israel Association for the

Study of Liver, Tel Aviv, 1/4/2014

New Challanges in Diagnosis and Treatment of Liver Diseases, Hadassah, Jerusalem

1/2013

Update in Management of Viral Hepatitis for general physicians & for viral hepatitis

patients, Jerusalem 2/2012

The European Association for the Study of Liver (EASL) "School of Hepatology in

“Hepatocellular Carcinoma (HCC)”, Jerusalem, June 2011

The EASL international annual meeting, Vienna, Austria 2010

The EASL international annual meeting, Copenhagen, Denmark 2009

The EASL annual meeting, Milan, Italy 2008

Active involvement (selection of topics, speakers and locations) in the organization

of many other EASL conferences (2007-2010):

Monothematic Conferences,

Schools of Hepatology,

Special conferences, Symposia (including industrial), e-series,

Annual Postgraduate Courses

EASL Joint meetings with international associations.


, 2017

6

Nazareth meeting for The World Hepatitis Awareness Day, 19th

May 2009

Nazareth meeting for The Liver Diseases Day, 9th

June 2010

Jerusalem meeting for The Liver Diseases Day, 24th

March 2010

Involved in the organization of special Nazareth conference. “The health status of

Arabic population along time axis”. Nazareth, 2009 to 2013

Italian Israeli scientific program on Hepatology (Italian Israeli Forum on Science &

Technology, Tel Aviv 28-29-30 April 2008)

Involvement in organizing all conferences and activities of Israeli Association for

the Study of Liver along 2003- 2006

Ad Hoc Reviewer (Scientific Journals) or reviewer of Peer- reviewed Journals:

Clinical Science (10 papers), Gut (5), Hepatology (7), Journal of Pharmacology and

Experimental Therapeutics (3), American J. of Physiology - Gastrointestinal & Liver

Physiology (3), Journal of Hepatology (3), Gastroenterology (2), PLoS ONE (8),

Digestive Diseases and Sciences (2), Medical Science Monitor (2), Journal of

Pharmaceutical Sciences (2), Liver International (3), Immunology (1), Tropical

Medicine & International Health (1), Liver Transplantation (1), Trends in Immunology

(1), Journal Of Viral Hepatitis (1), The European Journal of Pharmacology (1),

Archivum Immunologiae et Therapiae Experimentalis (1), Expert Opinion On Drug

Metabolism & Toxicology (1), Rivista Tumori (1), Human Imunology (1), FEBS Letters

(1), European Journal of Clinical Microbiology & Infectious Diseases (1), Harefuah (2).

Ad Hoc Reviewer (Grants) or reviewer of Grants or foundations:

2012-2014: BSF (American Israel Binational ScientificFoundation), 3 proposals

2014: Chief Scientist Fund, a review of 10 grant proposals

2011: Chief Scientist Fund, a review of 10 grant proposals

2010: Israel Science Foundation, a review of grant proposal

2009: Internal Hadassah Grants, a review of grant proposal

2009: Physiological Sciences, Grants Management Department. The Wellcome

Trust, The Gibbs Building, 215 Euston Road, London NW1 2BE

2009: Hadassah Internal Grant

2005: GIF (German Israel Foundation), a review of grant proposal

2004: Israel Cancer Association, a review of grant proposal

2003: The Korean National Grant, a review of grant proposal

7. MEMBERSHIP IN A PROFESSIONAL ASSOCIATION

Since 2000: Member, American Gastroenterology Association

Since 1998: Member, American Association for the Study of Liver Diseases

Since 1997: Member, European Association for the Study of the Liver


, 2017

7

Since 1996: Member, Israel Transplantation Society

Since 1996: Member, Israel Association for the Study of the Liver

Since 1996: Member, Israel Association for Gastroenterology & Hepatology

8. RESEARCH GRANTS

2015-2016 Kamin Fund, “The use of anti-neuroligin-4 (NLG4) receptor antibody to

ameliorate hepatic fibrosis through enhance killing potentials of NK cells”,

Approved on 09/06/2015, NIS 439,750 /year

2010-2011 Chief Scientist Fund, “Immune modulation of Hepatic Fibrosis: New

pathways for Lymphocytes and hepatic stellate cells interactions”,

Approved on 5/1/2010, NIS 300000/year. Manuscript#1, 8, 10-14.

2009-2013 Israel Scientific Foundation, “Immune modulation of Hepatic Fibrosis:

New pathways for Lymphocytes and hepatic stellate cells interactions”,

NIS 195000 a year for 4 years. Manuscript#10-14, 16, 23-25, 27, 28.

2009-2012 Deutsche Forschungsgemeinschaft German Research Foundation

(DFG), a trilateral German/ Israeli/ Palestinian grant: “Improved

Prevention of Perinatal hepatitis B transmission”, of total €1000000, my

part is €283104 for 3 years.

2007 Chief Scientist Fund, “Gene silencing for the immune modulation of

fibrosis”, Approved on 21/1/2007 but recommendation was referred to

Ezvonot award which I received NIS 200000/year

2006-2009: United States - Israel Bi-national Science Foundation (BSF), Approved

on 31/7/2006. “siRNA for the immune modulation of fibrosis”, Scott

Friedman, $30,000/45,000/ year for 4 years, Original Papers in Peer

Reviewed Journals, Manuscript#31-34.

2006 Chief Scientist Fund, “Pregnancy and Hepatic Fibrosis”, Approved on

27/6/2006 but no funding was available at same year, Manuscript#11.

2004-2006: Horowitz Fund, Approved on 2004. “Immune Modulation of Fibrosis”,

$40,000/40,000, Original Papers in Peer Reviewed Journals, manuscripts

#31-34

2004-2005: Compensatory Fund, Approved on 9/9/2004. “Immune Modulation of

Fibrosis Associated Hepatoma”, 90,000/90,000 NIS, Original Papers in

Peer Reviewed Journals, manuscripts #32 to #34

2004 Sylvia & David Salzberg Cancer Research Fund, “Anti-fibrosis effect of

Copaxone & IL-2 associated- hepatocellular carcinoma”, 0/90,000 NIS

(approved but only the Compensatory fund was provided), Original Papers

in Peer Reviewed Journals, manuscripts #31, 33

2004 Women Health Fund, “Pregnancy and Hepatic Fibrosis”, 0/90,000 NIS

(approved but only the Compensatory fund was provided). Manuscript#11.


, 2017

8

9. TEACHING AT THE HEBREW UNIVERSITY

A. Supervision of master and doctoral degree students in the last five years

Master's degree students:

M.Sc. student: 2014-2016 Ahmad Salhab, co-supervisor: Prof. Abd Al-Roof

Higazi, The role of NLG4 Receptor in the NK cells & immune modulation of

hepatic fibrosis (Oral Presentation #2-5, 8, 12 & Poster presentation #6, 7, 12,

14-16)

M.Sc. student: 2006-2011 Sarit Doron, co-supervisor: Prof. Eliot Berry, The role

of Endocanabinoid Receptor 2 in the immune modulation of hepatic fibrosis,

(Original Papers in Peer Reviewed Journals, manuscript#8, 10-14, 16, 23-25, 28,

30, 33, 35)

M.Sc. student: 2006-2009 Abdolnabi Maamoun, co-supervisor – Prof. Abd Al-

Roof Higazi, (BSF grant)

M.Sc. student: 2006-2008 Michaeli Rani, co-supervisor – Ronit Calderon. The

HBV vertical transmission in the vaccine era, (Other publications & Journals in

Foreign Languages, manuscript#3)

M.Sc. student: 2003-2006 El-Haj Madi, co-supervisor – Prof. Abd Al-Roof

Higazi, (Original Papers in Peer Reviewed Journals, manuscript#27, 63, 64)

Doctoral degree students:

Ph.D. student: 2008-2013 Abu-Tair Lina, co-supervisor: Prof. Eithan Galun, The

role of TLR9 in the immune modulation of hepatic fibrosis, (Poster presentation

2006th

and 2007th

AASLD meetings. Oral presentation 2008th

& 2010th

EASL

annual meetings & Original Papers in Peer Reviewed Journals, manuscript #8,

10-13, 16, 23)

Ph.D. student: 2004-2012 Muhanna Nidal, co-supervisor: Abd Al-Roof Higazi, ,

but also contributed to other studies later on (Original Papers in Peer Reviewed

Journals, manuscripts #1, 8, 23, 25, 27, 28, 30, 34, 35)

B. Post-doctoral Visitors

Laboratory Research co originator: Since 2007, Amer Johnny PhD. Laboratory

research coordinator supervising/ coordinating most of projects and students

Surgery Fellow: 2015-2016 Harbi KHALAYLEH. NK immune modulation

following Bariatric surgery.

Internal medicine fellow: 2013-2014 Hashim Bseso MD. Role of Alanin in NK

immune modulation via the nMDA receptor in NAFLD (Poster presentation #8,

13, 21)

Internal medicine fellow: 2013-2014 Nadav Ilani MD. The role of NLG4


, 2017

9

Receptor in the NK cells & immune modulation of hepatic fibrosis (Oral

Presentation #7)

Internal medicine fellow: 2006-2008 Mahmoud Mahamid MD. Amelioration of

hepatic fibrosis via Padma hepaten is associated with alternated natural killer t

lymphocytes (Original Papers in Peer Reviewed Journals, manuscript #7, 8, 13,

16, 23, 25 & Case Reposts 2,3)

Internal medicine fellow: 2003-2004 Gur Chamutal MD. Amelioration of

experimental colitis by Copaxone is associated with class-II-restricted CD4

immune blocking, but also contributed to other studies later on (Original Papers

in Peer Reviewed Journals, manuscript #12 & 33)

Pediatric medicine Fellow: 2003-2004 Horani Amjad MD. The Beneficial Effect

of Glatiramer Acetate (Copaxone®) on Immune Modulation of Experimental

Hepatic fibrosis, but also contributed to other studies later on (Original Papers in

Peer Reviewed Journals, manuscripts #14, 24, 25, 27, 28, 30, 34, 35. Also, case

report #4, 39, 41).

Internal medicine fellow: 2001-2002 Melhem Alaa MD. Anti-fibrotic activity of

NK cells in experimental liver injury through killing of activated HSC, (Original

Papers in Peer Reviewed Journals, manuscripts #27, 34, 35, 45, 48)

Doctoral Dissertation: 2012-2014 Lior Lupu, NLGN4X as a candidate gene for

NK cell impairment in mice model of nonalcoholic fatty liver disease (Poster

presentation #18)

Doctoral Dissertation: 2012-2013 Rivka villenchik, Screening of Lysosomal

Acid Lipase within cryptogenic liver disease with/ out microstaetosis (Oral

Presentation #1 & Poster presentation #3)

Doctoral Dissertation: 2008-2011 Ola Haj Yehya, Impact of Antigens HLA-Cw

AND epitopes C, Bw on liver transplantaion outcomes (Oral Presentation #20 &

Poster presentation #22)

Doctoral Dissertation: 2008-2010 Mohammad Masarwa, MRI in hepatic fibrosis

Doctoral Dissertation: 2006-2010 Hiba Zayyad, The anti tumoral effect of HSC

in hepatocellular carcinoma (Original Papers in Peer Reviewed Journals,

manuscript#8)

Doctoral Dissertation: 2003-2006 Wehbi Wehbi, The Beneficial Effect of

Glatiramer Acetate (Copaxone®) on Immune Modulation of Experimental

Hepatic fibrosis, (Original Papers in Peer Reviewed Journals, manuscript#33)

Doctoral Dissertation: 2003-2010 Greefat Rami, Role of Pregnancy in hepatic

fibrosis (Original Papers in Peer Reviewed Journals, manuscript#11)

Doctoral Dissertation: 2003-2004 Bishara Taiser, The role of NK cells related

killing receptors in hepatic fibrosis. Anti-fibrotic activity of NK cells in


, 2017

10

experimental liver injury through killing of activated HSC, (Original Papers in

Peer Reviewed Journals, manuscript#34)

Doctoral Dissertation: 2002-2003 Nassar Mithal, Anti-fibrotic activity of NK

cells in experimental liver injury through killing of activated HSC. (Original

Papers in Peer Reviewed Journals, manuscript#34)

Doctoral Dissertation: 2002-2003 Shehada Suhair, CD4 and CD8 secretion of

IL-4 and Interferon gamma in hepatic fibrosis. See acknowledgement: Immune

stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic

interleukin-10 from hepatocytes, (Original Papers in Peer Reviewed Journals,

see acknowledgement manuscript#46)

Doctoral Dissertation: 2000-2001 Abu-Fanni Rami, co-supervisor – Dr Abdulla

Haj-Yehia, Lipoic acid in TNB induced ulcerative colitis. This work

unfortunately was not published as Dr. Abdulla Haj-Yehia died (God rest his

soul) before completion the research.

C. Courses taught in the last 5 years

Bachelor's degree courses

Microbiology, third year medical students

Disease Process: third year pharmacy students.

Physical Examination, third year medical students

Master's degree courses

Tumor inducing viruses: Master’s students

MD's degree courses

Introduction to Internal Medicine, fourth year medical students

Problem Based Learning, fourth year medical students

Physical Examination, fourth year medical students

Clerkship in Internal Medicine & Gastroenterology, Bedside & Frontal

teaching, 4th

& 6th

year medical students


, 2017

11

LIST OF PUBLICATIONS:

Rifaat Safadi M.D.,

Total 159 = 68+42+6+5+6+12+20 (Subsequent to last promotion=29)

PI= principal investigator, C=co-researcher, S= student, T=lab tech. and in bold=

submitted chosen reprints best representing my research.

Doctoral Dissertation: MD. Thesis: Visualization of septum in cardiac computerized

tomography: Evidence of anemia. Prof. Bar-Ziv J, 1991, un-published.

Books: none.

Books Edited: none.

Chapters in Collections: none.

ARTICLES:

Original Papers in Peer Reviewed Journals (68):

1. Leitersdorf EPI

, Safadi RC, Meiner V

C, Reshef A

T, Bjorkhem I

C, Friedlander Y

C,

Markos SC, Berginer VM

PI, 1994. Cerebrotendinous Xanthomatosis in the Israeli

Druze: Molecular Genetics and Phenotypic Characteristics. Am J Hum Genet.

55:907-915. (10.794; 8/166; 49)

2. Reshef AT, Nissen H

C, Triger L

T, Hensen TS

C, Eliav O

T, Schurr D

C, Safadi R

C,

Gare MC, Leitersdorf E

PI. (1996). Molecular Genetics of familial

hypercholesterolemia in Israel. Hum Genet. 98:581-586. (5.138; 22/166; 24)

3. Safadi RPI

, Shouval DC, Tur-Kaspa R

C, Ashur Y

C and Ilan Y

PI. (1996). Beneficial

effect of Ribavirin on hepatitis C associated cryoglobulinemia post liver

transplantation. Liver Transplant Surgery*. 2:263-269. (*since 1999 continued by

Liver Transplantation) (3.951; 18/79; 11/200; 5/25; 12)

4. Zimmerman JPI

, Shouhat VC, Tsvang E

C, Arnon R

C, Safadi R

C, Wengrower D

PI.

(1997). Esophagitis is a major cause of upper gastrointestinal hemorrhage in the

elderly. Scand J Gastroenterol. 32:906-909. (2.199; 50/79; 31)

5. Safadi RPI

, Ligumsky MC, Goldin E

C, Ilan Y

C, Nusair S

C. (1998). Increased serum

CA 19-9 antibodies in Sjogren’s syndrome. Postgrad Med J. 74:543-544. (1.633;

58/155; 13)

6. Adler RC, Safadi R

C, Caraco Y

C, Rowe M

C, Etzioni A

C, Ashur Y

C, Galun E

C,

Shouval DPI

. (1999). Comparision of immune reactivity and pharmacokinetics of


, 2017

12

two Hepatitis B Immune Glubulines in patients after liver transplantation.

Hepatology. 29:1299-12305. (11.711; 4/79; 24)

7. Haviv Y.SC, Sharkia M

C, Safadi R

PI. (2000). Hypoglycemia in patients with renal

failure. Renal Failure. 22:219-223. (0.875; 64/77; 28)

8. Kitay-Cohen YC, Amiel A

C, Hilzenrat N

C, Buskila D

C, Ashur Y

C, Fejgin M

C, Gaber

EC, Safadi R

C, Tur-Kaspa R

C, Lishner M

PI. (2000). Bcl-2 rearrangement in patients

with chronic hepatitis C associated with essential mixed cryoglobulinemia type II.

Blood. 96:2910-2. (11.847; 2/70; 60)

9. Safadi RPI

, Ergunay KC, Ilan Y

C, Klein A

C, Shouval D

C, Manny N

C, Harush N

C,

Galun EPI

. (2000). TT virus infection in Israeli patients with fulminant hepatic

failure. Vox Sang. 79:242-5. (2.656; 36/70; 2)

10. Durst RYC, Goldsmidt N

C, Namestnick J

C, Safadi R

C, Ilan Y

PI. (2001). Familial

cluster of fulminant hepatitis-A infection. J Clin Gastroenterol. 32:453-4. (3.163;

28/79; 12)

11. Safadi RPI

, Or RC, Ilan Y

C, Naparstek E

C, Nagler A

C, Klein A

C, Ketzinel-Gilaad

MC, Ergunay K

C, Danon D

C, Shouval D

C, Galun E

PI. (2001). Lack of known

hepatitis virus in hepatitis-associated aplastic anemia and outcome after bone

marrow transplantation. Bone Marrow Transplant. 27:183-90. (3.636; 71/213;

21/70; 54/151; 43)

12. Levy MPI

, Safadi RC, Zylber-Katz E

C, Granit L

C, Caraco Y

PI. (2001). Impairment of

the metabolism of dipyrone in asymptomatic carriers of the hepatitis-B virus does

not occur in rapid acetylators. Eur J Clin Pharmacol. 57:461-5. 2. (2.710; 93/255; 4)

13. Bishara AC, Brautbar C

C, Eid A

C, Scherman L

T, Ilan Y

C, Safadi R

PI. (2002). Is

presensitization relevant to liver transplantation outcome? Hum Immunol.

63(9):742-50. (2.127; 112/151; 24)

14. Shibolet OC, Ilan Y

C, Gillis S

C, Hubert A

C, Shouval D

C, Safadi R

PI. (2002).

Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus

reactivation in hepatitis B surface antigen carriers. Blood. 100:391-6. (11.847; 2/70;

110)

15. Kogan JC, Safadi R

C, Ashur Y

C, Shouval D

C, Ilan Y

PI. (2002). Prognosis of

symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients. J

Clin Gastroenterol. 35:75-81. (3.163; 28/79; 56)

16. Galun EC, Eren R

C, Safadi R

C, Ashour Y

C, Terrault N

C, Keeffe EB

C, Matot E

C,


, 2017

13

Mizrachi SC, Terkieltaub D

C, Zohar M

C, Lubin I

C, Gopher J

C, Shouval D

C, Dagan

SPI

. (2002). Clinical evaluation (phase I) of a combination of two human monoclonal

antibodies to HBV: safety and antiviral properties. Hepatology. 35:673-9. (11.711;

4/79; 38)

17. Menachem YC, Safadi R

C, Ashur Y

C, Ilan Y

PI. (2003). Malignancy after liver

transplantation in patients with premalignant conditions. J Clin Gastroenterol.

36:436-9. (3.163; 28/79; 9)

18. Safadi RPI

, Israeli EC, Pappo O

C, Shibolet O

C, Melhem A

C, Bloch A

C, Rowe M

T,

Alper RT, Klein A

T, Hemed N

T, Segol O

C, Thalenfeld B

C, Engelhardt D

C, Rabbani

EC, Ilan Y

PI. (2003). Treatment of chronic hepatitis B virus infection via oral

immune regulation toward hepatitis B virus proteins. Am J Gastroenterol. 98:2505-

15. 5. (10.383; 6/79; 27)


C, Kalish Y

C, Safadi R

C, Ashur Y

C, Eid A

C, Shouval D

C, Wolf

DPI

. (2003). Late cytomegalovirus infection occurring two or more years following

liver transplantation: a report of seven cases and review of the literature. Transpl Int.

16:861-5. (2.835; 40/200; 24)

20. Schmilovitz-Weiss HPI

, Ben-Ari ZC, Sikuler E

C, Zuckerman E

C, Sbeit W

C,

Ackerman ZC, Safadi R

C, Lurie Y

C, Rosner G

C, Tur-Kaspa R

C, Reshef R

PI. (2004).

Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int. 24:547-

51. (4.470; 13/79; 55)

21. Shibolet OPI

, Elinav EC, Ilan Y

C, Safadi R

C, Ashur Y

C, Eid A

C, Zamir G

C,

Fridlander MC, Bdolah-Abram T

C, Shouval D

PI, Admon D

PI. (2004). Reduced

incidence of hyperuricemia, gout, and renal failure following liver transplantation in

comparison to heart transplantation: a long-term follow-up study. Transplantation.

77:1576-80. (3.690; 53/151; 15/200; 9/25; 11)

22. Wald OC, Pappo O

C, Safadi R

C, Dagan-Berger M

C, Beider K

C, Wald H

C, Franitza

SC, Weiss I

C, Avniel S

C, Boaz P

C, Hanna J

C, Zamir G

C, Eid A

C, Mandelboim O

C,

Spengler UC, Galun E

C, Peled A

PI. (2004). Involvement of the CXCL12/CXCR4

pathway in the advanced liver disease that is associated with hepatitis C virus or

hepatitis B virus. Eur J Immunol. 34:1164-74. (4.179; 42/151; 64)

23. Israeli EPI

, Safadi R*PI

, Melhem AC, Pappo O

C, Shibolet O

C, Klein A

T, Hemed N

T,

Thalenfeld BC, Engelhardt D

C, Rabbani E

C, Ilan Y

PI. (2004). Induction of oral

immune regulation towards liver extracted proteins for treatment of chronic HBV


, 2017

14

and HCV hepatitis: Results of a phase I clinical trial. Liver Int. 24:295-307. (4.470;

13/79; 14). *First 2 shared equally.

24. Safadi R*PI

, Ohta MC, Alvarez CE

C, Fiel I

C, Bansal M

C, Mehal W

C, Friedman SL

PI.

(2004). Immune Stimulation of Hepatic Fibrogenesis by CD8 Lymphocytes and its

Attenuation by Transgenic Interleukin 10 from Hepatocytes. Gastroenterology.

127:870–882. (18.187; 1/79; 119) (*See also Editorial: G. Ramadori, B. Saile, 2004.

Inflammation, Damage Repair, Immune Cells, and Liver Fibrosis: Specific or

Nonspecific, This Is the Question. Gastroenterology. 127:997-1000).

25. Margalit MPI

, Ilan YPI

, Ohana MC, Safadi R

C, Alper R

C, Sherman Y

C, Doviner V

C,

Rabbani EC, Engelhardt D

C, Nagler A

PI. (2005). Adoptive transfer of small numbers

of DX5+ cells alleviates graft-versus-host disease in a murine model of

semiallogeneic bone marrow transplantation: a potential role for NKT lymphocytes.

Bone Marrow Transplant. 35:191-7. (3.636; 71/213; 21/70; 54/151; 18)

26. Bansal MBPI

, Kovalovich KC, Gupta R

C, Li W

C, Agarwal A

C, Radbill B

C, Alvarez

CEC, Safadi R

C, Fiel MI

C, Friedman SL

PI, Taub RA

PI. (2005). Interleukin-6 protects

hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2

expression. J Hepatol. 42:548-56. 6.073;4/48;17 (10.590; 5/79; 62)

27. Shibolet OPI

, Rowe MC, Safadi R

C, Levy I

C, Zamir G

C, Eid A

C, Donchin Y

C, Ilan

YC, Shouval D

PI. (2005). Air transportation of patients with end-stage liver disease

to distant liver transplantation centers. Liver Transpl. 11:650-655. (3.951; 18/79;

11/200; 5/25; 5)

28. Safadi RPI

, Alvarez CEC, Ohta M

C, Brimnes J

C, Kraus T

C, Mehal W

C, Bromberg J

C,

Friedman SLPI

. (2005). Enhanced Oral Tolerance in Transgenic Mice with

Hepatocyte Secretion of Interleukin-10. J Immunol. 175:3577-83. (4.985; 32/151; 6)

29. Karban API

, Atia OC, Leitersdorf E

C, Shahbari A

C, Sbeit W

C, Ackerman Z

C, Mualem

RC, Levine A

C, Nesher S

C, Safadi R*

PI, Eliakim R

PI. (2005). The relation between

NOD2/CARD15 Mutations and the Prevalence and Phenotypic Heterogeneity of

Crohn's Disease: Lessons from the Israeli Arab Crohn's Disease Cohort. Dig Dis Sci.

50:1692-7. (2.516; 42/79; 15). *Last 2 shared equally

30. Bishara API

, Brautbar CC

, Zamir GC

, Eid AC

, Safadi RPI

. (2005). Killer Inhibitory

Receptors (KIR) Mismatching and Liver Transplantation Outcome. Hum Immunol.

66:1099-105. (2.127; 112/151; 26)

31. Gur CC, Karussis D

C, Golden E

C, Doron S

C, Ilan Y

C, Safadi R

PI. (2006).


, 2017

15

Amelioration of experimental colitis by Copaxone is associated with class-II-

restricted CD4 immune blocking. Clin Immunol. 118:307-16. (4.034; 45/151; 11)

32. Melhem AC, Muhanna N

C, Bishara A

C, Alvarez CE

C, Ilan Y

C, Bishara T

C, Horani

AC, Nassar M

C, Friedman SL

C, Safadi R

PI. (2006). Anti-fibrotic Activity of NK

cells in Experimental Liver Injury through Killing of Activated HSC. J Hepatol.

45:60-71. (10.590; 5/79; 108)

33. Horani AC, Muhanna N

C, Pappo O

C, Melhem A

C, Alvarez CE

C, Doron S

T, Wehbi

WC, Friedman SL

C, Safadi R

PI. (2007). The Beneficial Effect of Glatiramer Acetate

(Copaxone®) on Immune Modulation of Experimental Hepatic fibrosis. Am J

Physiol Gastrointest Liver Physiol. 292:G628-38. (3.297; 27/79; 22/83; 14)

34. Galun EPI

, Terrault NAC, Eren R

C, Zauberman A

C, Nussbaum O

C, Terkieltaub D

C,

Zohar MC, Buchnik R

C, Ackerman Z

C, Safadi R

C, Ashur Y

C, Misrachi S

C, Liberman

YC, Rivkin L

C, Dagan S

PI. (2007). Clinical evaluation (Phase I) of a human

monoclonal antibody against hepatitis C virus: Safety and antiviral activity. J

Hepatol. 46:37-44. (10.590; 5/79; 26)

35. Muhanna NC, Horani A

C, Doron S

T, Safadi R

PI. (2007). Lymphocyte-hepatic stellate

cell proximity suggests a direct interaction. Clin Exp Immunol. 148 (2), 338–347.

(3.148; 63/151; 33)

36. Safadi RPI

, Zigmond EC, Pappo O

C, Shalev Z

C, Ilan Y

PI. (2007). Amelioration of

hepatic fibrosis via beta-Glucosylceramide mediated immune modulation is

associated with altered CD8 and NKT lymphocyte distribution. Int Immunol.

19:1021-9. (Retracted) (3.031; 66/151; 28)

37. Elinav EPI

, Pinsker GC, Safadi R

C, Pappo P

C, Bromberg M

C, Anis E

C, Keinan-Boker

LC, Broide E

C, Ackerman Z

C, Nitzan Kaluski D

C, Lev B

C, Shouval D

PI. (2007).

Association between Consumption of Herbalife® Nutritional Supplements and

Acute Hepatotoxicity. J Hepatol. 47:514-20. (10.590; 5/79; 59)

38. Muhanna NC, Doron S

T, Wald O

C, Horani A

C, Eid A, Pappo O, Friedman SL,

Safadi RPI

. (2008). Activation of Hepatic Stellate Cells following Phagocytosis of

Lymphocytes – a Novel Pathway of Fibrogenesis. Hepatology. 48:963-77. (11.711;

4/79; 48)

39. Higazi API

, El-Haj MPI

, Melhem AC, Horani A

C, Pappo O

C, Alvarez CE

C, Muhanna

NC, Friedman SL

C, Safadi R

PI. (2008). Immunomodulatory Effects of Plasminogen

Activators on Hepatic Fibrogenesis. Clin Exp Immunol. 152:163-73. (3.148; 63/151;


, 2017

16

11)

40. Maor YPI

, Schapiro JMC, Bashari D

C, Lurie Y

C, Safadi R

C, Segol O

C, Paritsky M

C,

Rachlis ZC, Avidan B

C, Bar-Meir S

C, Martinowitz U

PI. (2008). Treatment of

hepatitis C in patients with haemophilia - the Israeli National Hemophilia Center

experience. Haemophilia. 14:336-42. (2.673; 35/70; 6)

41. Ginsburg IC, Koren E

C, Horani A

C, Mahamid M

C, Doron S

T, Muhanna N

C, Amer J

C,

Safadi RPI

. (2009). Amelioration of hepatic fibrosis via Padma Hepaten is

associated with altered NKT lymphocytes. Clin Exp Immunol. 157:155-64. (3.148;

63/151; 8)

42. Ackerman ZPI

, Oron-Herman MC, Pappo O

C, Peleg E

C, Safadi R

C, Schmilovitz-

Weiss HC, Grozovski M

PI. (2010). Hepatic effects of rosiglitazone in rats with the

metabolic syndrome. Basic Clin Pharmacol Toxicol. 107:663-8. (3.097; 72/255;

24/90; 18)

43. Chang TTPI

, Liaw YFC, Wu SS

C, Schiff E

C, Han KH

C, Lai CL

C, Safadi R

C, Lee SS

C,

Halota WC, Goodman Z

C, Chi YC

C, Zhang H

C, Hindes R

C, Iloeje U

C, Beebe S

C,

Kreter BPI

. (2010). Long-term entecavir therapy results in the reversal of

fibrosis/cirrhosis and continued histological improvement in patients with chronic

hepatitis B. Hepatology. 52:886-93. (11.711; 4/79; 338)

44. Tromm API

, Bunganič IC, Tomsová E

C, Tulassay Z

C, Lukáš M

C, Kykal J

C, Bátovsk

MC, Fixa B

C, Gabalec L

C, Safadi R

C, Kramm HJ

C, Altorjay I

C, Löhr H

C,

Koutroubakis IC, Bar-Meir S

C, Štimac D

C, Dilger K

C, Mohrbacher R

C, Greinwald

RPI

, and The International Budenofalk® Study Group

C. Budesonide (9 mg) is at Least

as Effective as Mesalamine (4.5 g) in Patients with Mildly to Moderately Active

Crohn's disease. (2011). Gastroenterology. 140:425-434. (18.187; 1/79; 45)

45. Safadi RPI

, Xie QC, Chen Y

C, Yin YK

C, Wei L

C, Hwang SG

C, Zuckerman E

C, Jia

JDC, Lopez P

PI. (2011). Efficacy of Switching to Telbivudine in Chronic Hepatitis B

Patients Previously Treated with Lamivudine. Liver Int. 31:667-75. (4.470; 13/79; 4)

46. Muhanna NC, Abu Tair L

C, Doron S

T, Amer J

C, Azzeh M

C, Mahamid M

C, Friedman

SPI

, Safadi RPI

. (2011). Amelioration of hepatic fibrosis by NK cell activation. Gut.

60:90-8. (14.921; 2/79; 35)

47. Horani API

, Shoseyov DPI

, Doron ST, Mruwat R

C, Amer J

C, Kerem E

PI, Safadi R

PI.

(2011). Immune modulation of ovalbumin-induced lung injury in mice using β-

glucosylceramide and a potential role of the liver. Immunobiology. 216:548-57.


, 2017

17

(2.781; 77/151; 3)

48. May DPI

, Djonov VC, Zamir G

C, Bala M

C, Safadi R

C, Sklair-Levy M

C, Keshet E

PI.

(2011). A Transgenic Model for Conditional Induction and Rescue of Portal

Hypertension Reveals a Role of VEGF-Mediated Regulation of Sinusoidal

Fenestrations. PLoS One. 6(7):e21478. (3.057; 11/63; 17)

Subsequent to last promotion------------------------------------------------------------

49. Sela YPI

, Freiman MC, Dery E

C, Edrei Y

C, Safadi R

C, Pappo O

C, Joskowicz L

PI,

Abramovitch RPI

. (2011). fMRI-based hierarchical SVM model for the classification

and grading of liver fibrosis. IEEE Trans Biomed Eng. 58(9):2574-81. (2.468;

22/76; 12)

50. Gur CPI

, Doron ST, Kfir-Erenfeld S

C, Horwitz E

C, Abu-tair L

C, Safadi R

PI/Equal

contribution, Mandelboim O

PI. (2012). NKp46-mediated killing of human and mouse

hepatic stellate cells attenuates liver fibrosis. Gut. 61(6):885-93. (14.921; 2/79; 34)

51. Avraham YPI

, Amer JPI

, Doron SC, Abu-Tair L

C, Mahamid M

C, Khatib AA

C, Berry

EMC, Safadi R

PI. (2012). The direct pro-fibrotic and indirect immune anti-fibrotic

balance of blocking the cannabinoid CB2 receptor. Am J Physiol Gastrointest Liver

Physiol. 15;302(12):G1364-72. (3.297; 27/79; 22/83; 4)

52. Horani API

, Shoseyov DPI

, Ginsburg IC, Mruwat R

C, Doron S

T, Amer J

C, Safadi R

PI.

(2012). Triphala (PADMA) extract alleviates bronchial hyperreactivity in a mouse

model through liver and spleen immune modulation and increased anti-oxidative

effects. Ther Adv Respir Dis. 6(4):199-210. (2.286; 31/58; 1)

53. Chan HLPI

, Chen YCC, Gane EJ

C, Sarin SK

C, Suh DJ

C, Piratvisuth T

C, Prabhakar

BC, Hwang SG

C, Choudhuri G

C, Safadi R

C, Tanwandee T

C, Chutaputti A

C,

Yurdaydin CC, Bao W

C, Avila C

C, Trylesinski A

PI. (2012). Randomized clinical

trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients

with HBV-related decompensated cirrhosis. J Viral Hepatitis. 19(10):732-743.

(4.179; 17/79; 15/83; 8/33; 45)

54. Abu-tair LC, Doron S

T, Mahamid M

C, Amer J

C, Safadi R

PI. (2013). Leptin

modulates lymphocytes adherence to hepatic stellate cells is associated with

oxidative status alterations. Mitochondrion. Sep;13(5):473-80. (3.647; 78/187;

48/166; 2)

55. MuhannaPI

N, Doron ST, Abu-tair L

C, Hiba Zayyad

C, Mahamid M

C, Amer J

C, Safadi

RPI

. (2013). Early fibrosis inhibits hepatocellular carcinoma and is associated with


, 2017

18

free radical effects. Mitochondrion. Sep;13(5):391-8. (3.647; 78/187; 48/166; 1 )

56. Eyal OPI

, Aharon MC, Safadi R

C, Elhalel M.D

PI. (2013). Serum vitamin D levels in

kidney transplant recipients: the importance of an immunosuppression regimen and

sun exposure. Isr Med Assoc J. Oct;15(10):628-33. (0.879; 99/155; 3)

57. Abu-Tair LPI

, Axelrod JHC, Doron S

T, Ovadya Y

C, Krizhanovsky V

C, Galun E

C,

Amer JPI

, Safadi RPI

. (2013). Natural killer cell-dependent anti-fibrotic pathway in

liver injury via Toll-like receptor-9. PLoS One. 8(12):e82571. (3.057; 11/63; 4)

58. Amer JPI

, Grifat RC, Doron S

T, Abu-Tair L

C, Mruwat R

C, El-Khatib A

C, Safadi R

PI.

(2014). The pro-fibrotic effects of pregnancy in a carbon-tetrachloride-induced liver

injury in mouse model. Liver Int. 34(8):1232-40. (4.470; 13/79; 0)

59. Safadi RPI

, Konikoff F.MC, Mahamid M

C, Zelber-Sagi S-C, HalpernM

C, Gilat T

C,

Oren RPI

and FLORA Group. A Phase-2 Randomized, Double blind, Placebo-

Controlled Trial of Aramchol for Non-Alcoholic Fatty Liver Disease. (2014). Clin

Gastroenterol Hepatol. 12(12):2085-91.e1. (7.680; 7/79; 18)

60. Saraswat V, Norris S, de Knegt RJ, Sanchez Avila JF, Sonderup M, Zuckerman E,

Arkkila P, Stedman C, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V,

Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blach S, Blokhina N,

Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj YA,

Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Vree M, Estes C, Flisiak R,

Gadano AC, Gane E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J,

Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P,

Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Mossong J,

Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts,

Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Puri P, Radke S,

Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi Rc,

Sagalova O, Sanduijav R, Schréter I, Seguin-Devaux C, Shah SR, Shestakova I,

Shevaldin A, Shibolet O, Sokolov S, Souliotis K, Spearman CW, Staub T,

Strebkova EA, Struck D, Tomasiewicz K, Undram L, van der Meer AJ, van Santen

D, Veldhuijzen I, Villamil FG, Willemse S, Zuure FR, Silva MO, Sypsa V, Gower

E. (2015). Historical epidemiology of hepatitis C virus (HCV) in select countries -

volume 2. J Viral Hepatitis. Jan;22 Suppl 1:6-25. (4.179; 17/79; 15/83; 8/33; 13)

61. Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schréter I,

Baatarkhuu O, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Arkkila P,


, 2017

19

Barclay K, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Cisneros L,

Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D,

de Knegt RJ, de Vree M, Estes C, Flisiak R, Gane E, Gower E, Halota W,

Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P,

Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A,

Mamonova N, Mendez-Sanchez N, Norris S, Nurmukhametova E, Nymadawa P,

Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-

Sing N, Prins M, Radke S, Rakhmanova A, Razavi-Shearer K, Reesink HW,

Ridruejo E, Safadi Rc, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V,

Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Silva MO,

Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C,

Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ,

van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR,

Puri P, Razavi H. (2015). The present and future disease burden of hepatitis C virus

(HCV) infections with today's treatment paradigm - volume 2. J Viral Hepatitis.

Jan;22 Suppl 1:26-45. (4.179; 17/79; 15/83; 8/33; 28)

62. Gane E, Kershenobich D, Seguin-Devaux C, Kristian P, Aho I, Dalgard O,

Shestakova I, Nymadawa P, Blach S, Acharya S, Anand AC, Andersson MI, Arendt

V, Arkkila P, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blokhina

N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj

YA, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Gadano AC,

Gower E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J, Houlihan D,

Hrusovsky S, Jarčuška P, Kostrzewska K, Leshno M, Lurie Y, Mahomed A,

Mamonova N, Mendez-Sanchez N, Mossong J, Norris S, Nurmukhametova E,

Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prins M,

Puri P, Radke S, Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW,

Ridruejo E, Safadi Rc, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V,

Schréter I, Shah SR, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M,

Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V,

Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil

FG, Willemse S, Zuckerman E, Zuure FR, Prabdial-Sing N, Flisiak R, Estes C.

(2015). Strategies to manage hepatitis C virus (HCV) infection disease burden -

volume 2. J Viral Hepatitis. Jan;22 Suppl 1:46-73. (4.179; 17/79; 15/83; 8/33; 14)


, 2017

20

63. Marcellin P, Wursthorn K, Wedemeyer H, Chuang WL, Lau G, Avila C, Peng CY,

Gane E, Lim SG, Fainboim H, Foster GR, Safadi RC, Rizzetto M, Manns M, Bao

W, Trylesinski A, Naoumov N. Telbivudine plus pegylated interferon alfa-2a in a

randomized study in chronic hepatitis B is associated with an unexpected high rate

of peripheral neuropathy. (2015). J Hepatol. 62(1):41-7. (10.590; 5/79; 15)

64. Ron Y, Halpern Z, Safadi RC, Dickman R, Dekel R, Sperber AD. Safety and

efficacy of the vibrating capsule, an innovative non-pharmacological treatment

modality for chronic constipation. (2015). Neurogastroenterol Motil. 27(1):99-104.

(3.310; 26/79; 57/193; 92/256; 1)

65. Muhanna N, Amer J, Salhab A, Sichel JY, Rifaat SafadiPI

. The immune interplay

between thyroid papillary carcinoma and hepatic fibrosis. (2015). PLoS One.

7;10(7):e0132463. (3.057; 11/63; 0)

66. Shteyer E, Villenchik R, Mahamid M, Nator N, Rifaat SafadiPI

. Low Serum

Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease (2016). Int

J Mol Sci. 17(3):312. (3.257; 110/289; 52/163; 2)

67. Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D,

Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi RC, Baruch Y,

Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit

J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S. Daclatasvir vs telaprevir

plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. (2016). World J

Gastroenterol. 22(12):3418-31. (2.787; 38/79; 1)

68. Kleinstern G, Abu Seir R, Perlman R, Abdeen Z, Khatib A, Elyan H, Dann EJ,

Kedmi M, Ellis M, Nagler A, Amir G, Ben Yehuda D, Rifaat SafadiPI

*, Paltiel O.

Associations between B-cell non-Hodgkin lymphoma and exposure, persistence and

immune response to Hepatitis B. (2016). Haematologica. 101(7):e303-5. *O.P and R.S

contributed equally to this study. (6.671; 4/70; 0)


, 2017

21

Case Reports (42):

1. Safadi RPI

, Orbach HC, Ilan Y

C, Ben-Chetrit E

PI. (1993). Refractory hemolytic

anemia a rare manifestation of mixed connective tissue disease. Eur J Intern Med.

4:235-238. (2.591; 31/155; 0)

2. Putterman CC, Safadi R

C, Zlotagora J

C, Banura R

C, Eldor A

PI. (1993). Treatment of

the hematological manifestations of dyskeratosis congenita. Ann Hematol. 6:209-

212. (3.022; 31/70; 13)

3. Safadi RPI

, Or RC, Bar-Ziv J

C, Poliak A

PI. (1994). Lymphoma associated

pancreatitis as a presenting manifestation of immunoblastic lymphoma. Leuk

Lymph. 12: 317-319. (3.093; 95/213; 28/70; 5)

4. Putterman DC, Safadi R

C, Ilan Y

C, Ben-Chetrit E

PI. (1994). Pulmonary embolism as

the first presenting feature of hepato-cellular carcinoma. Presse Med. 23:474-476.

(1.015; 87/155; 1)

5. Shustin LC, Haviv YS

C, Weinberger M

C, Safadi R

PI. (1995). Talc granuloma of

uterus. Eur J Med Res. 1:49-50. (1.684; 84/124; 1)

6. Safadi RPI

, Ilan YC, Friedman G

C, Bar Ziv J

C, Raz I

PI. (1995). Solitary calf abscess

in a patient with infective endocarditis. Eur J Intern Med. 6:129-130. (2.591;

31/155; 0)

7. Safadi RPI

, Levy IC, Amitai Y

C, Caraco Y

PI. (1995). Beneficial effect of Digoxin-

specific Fab antibody fragments in Oleander intoxication. Arch Intern Med.

155:2121-2125. (14.000; 6/155; 36)

8. Sviri SC, Gavert N

C, Ger M

C, Safadi R

PI. (1995). Citrobacter Diversus endocarditis

following a dog bite. Eur J Intern Med. 6:175-176. (2.591; 31/155; 0)

9. Yossepowich OC, Safadi R

C, Chajek-Shaul T

PI. (1995). Resistance to activated

protein C: A new approach to hypercoagulable states. Isr J Med Sci. 31:510-512.

(0.879; 99/155; 1)

10. Safadi RPI

, Pappo OC, Okon E

C, Sviri S

C, Eldor A

PI. (1996). Merkel cell tumor in a

woman with chronic lymphocytic leukemia. Leuk Lymph. 20:509-511. (3.093;

95/213; 28/70; 15)

11. Safadi RPI

, Almog YC, Dranitzki-Elhalel M

C, Rosenmann E

C, Tur-Kaspa R

PI.

(1996). Glomerulonephritis Associated with Acute Hepatitis B. Am J Gastroenterol.

91:138-139. (10.383; 6/79; 3)

12. Cohen SEC, Raz I

C, Safadi R

PI. (1996). A patient with hypoparathyroidism,


, 2017

22

dysmorphic features and mental retardation. Eur J Med Res. 1:266-268. (1.684;

84/124; 2)

13. Cohen SEC, Ligumsky M

C, Bar-Ziv J

C, Safadi R

PI. (1996). Benign presentation of

an ERCP induced abdominal abscess. Eur J Med Res. 1:404-406. (1.684; 84/124; 0)

14. Safadi RPI

, Ben-Hur TC, Shouval D

PI. (1996). Mononeuritis multiplex, a rare

complication of acute hepatitis A virus infection. Liver. 16:288-289. (4.470; 13/79;

7)

15. Safadi RPI

, Sviri SC, Eid A

C, Lebensart P

PI. (1996). Gallbladder varices: a case

report and review of the literature. Eur J Med Res. 1:506-508. (1.684; 84/124; 6)

16. Safadi RPI

, Dranitzki-Elhalel MC, Popovtzer M

C, Ben-Yehuda A

PI. (1996).

Metformin- induced lactic acidosis with acute renal failure. Am J Nephrol. 16:520-

522. (2.605; 24/77; 20)

17. Haviv YSC, Pikarski A

C, Shiloni E

C, Safadi R

PI. (1996). A late retroperitoneal

hematoma mimicking acute appendicitis- an unusual complication of coronary

angioplasty. Eur J Med Res. 1:591-592. (1.684; 84/124; 3)

18. Yossepowich OC, Sviri S

C, Ben-Yehuda A

C, Eid A

C, Safadi R

PI. (1996). Salmonella

infection and pneumonia. Eur J Med Res. 1:589-590. (1.684; 84/124; 0 )

19. Haviv YSC, Breuer R

C, Sviri S

C, Safadi R

PI. (1997). CT-guided biopsy of peripheral

lung lesions associated with BOOP. Eur J Med Res. 2:44-46. (1.684; 84/124; 8)

20. Yossepowich OC, Amir G

C, Safadi R

C, Lossos I.S

PI. (1997). Ischemic hepatitis

associated with toxic epidermal necrolysis in a cirrhotic patient treated with

Cefuroxime. Eur J Med Res. 2(4):182-4. (1.684; 84/124; 6)

21. Sviri SC, David R

C, Bodur I

C, Safadi R

C, Libson E

C, Ben-Yehuda A

PI. (1997).

Legionella Feeleii Pneumonia and Pericarditis. J Infection. 34:277-279. (4.382;

13/83; 5)

22. Safadi RPI

, Ashur YC, Ilan I

C, Shouval D

PI. (1997). Hepatitis C-associated

cryoglobulinemia presenting with pericardial effusion. Am J of Gastroent. 92:710-

712. (10.383; 6/79; 7)

23. Yossepowich OC, Chajek-Shaul T

C, Rubinow A

C, Safadi R

PI. (1997). Resistance to

activated protein C: Arterial thrombosis associated with autoimmune features. Eur J

Med Res. 2:355-357. (1.684; 84/124; 2)

24. Cohen SEC, Safadi R

C, Verstandig A

C, Eid A

C, Sasson T

C, Lev S

C, Shouval D

PI.

(1997). Liver-spleen infarcts following transcatheter chemoembolization: A case


, 2017

23

report and review of the literature. Dig Dis Sci. 42:938-943. (2.516; 42/79; 12)

25. Safadi RPI

, Gotsman O, Friedlaender MC, Rubinger D

C, Popovtzer MM

PI. (1997).

Renal failure, paraproteinemia and lung squamous cell carcinoma. Renal Failure.

19:495-498. (0.875; 64/77; 0)

26. Safadi RPI

, Berkman NC, Haviv YS

C, Ben-Yehuda A

C, Amir G

C, Naparstek Y

PI.

(1997). Primary Non-Hodgkin’s lymphoma of the lung presented as bronchiolitis

obliterans organizing pneumonia. Leuk Lymph. 28:209-213. (3.093; 95/213; 28/70;

8)

27. Haviv YSC, Safadi R

PI. (1998). Rapid progression of scleroderma associated with

Penicillamine therapy. Clin Drug Invest. 15:61-63. (1.806; 165/255; 0)

28. Haviv YSC, Goldschmidt N

C, Safadi R

PI. (1998). Pitutary apoplexy manifested by

sterile meningitis. Eur J Med Res. 3:263-264. (1.684; 84/124; 8)

29. Rashkovsky IC, Safadi R

C, Zlotogorski A

PI. (1998). Black Palmar macules. Arch

Dermatol. 134:1020,1023-1024. (5.097; 4/61; 3)

30. Haviv YSC, Rubinger D

C, Zamir E

C, Safadi R

PI. (1998). Pseudo-normal osmolal and

anion gaps following simultaneous ethanol and methanol ingestion. Am J Nephrol.

18:436-438. (2.605; 24/77; 11)

31. Haviv YSC, Kramer MR

C, Safadi R

PI. (1998). Idiopathic pulmonary fibrosis

associated with rectal carcinoma- a paraneoplastic syndrome or coincidence? Am J

Gastroenterol. 93:838-839. (10.383; 6/79; 0)


PI. (1998). Normotensive scleroderma renal crisis- case report

and review of the literature. Renal Failure. 20:733-736. (0.875; 64/77; 10)

33. Haviv YSC, Zimmerman M

C, Berkman N

C, Safadi R

PI. (1999). Fumaric acid ester-

induced diffuse renal tubular injury presenting as Fanconi’s syndrome. Clin Drug

Invest. 17:333-335. (1.806; 165/255; 2)

34. Safadi RPI

, Riever YC, Haviv YS

C, Ilan Y

PI. (1999). [Neurological manifestation in

Non A-G hepatitis]. Harefuah. 136:368-370 [Hebrew]. (X; X; 1)


C, Zamir E

PI. (1999). A rapidly progressive cataract in a patient

with autoimmune hypoparathyroidism and acute liver and renal failure. Am J

Nephrol. 19:523-526. (2.605; 24/77; 2)

36. Haviv YSC, Sharkia M

C, Galun E

C, Safadi R

PI. (2000). Pancreatitis following

hepatitis A vaccination. Eur J of Med Res. 5:229-230. (1.684; 84/124; 3)

37. Morali GC, Safadi R

C, Pappo O

C, Jurim O

C, Shouval D

PI. (2002). Caustic sclerosing


, 2017

24

cholangitis treated with orthotopic liver transplantation. Isr Med Assoc J. 4:1152-3.

(0.879; 99/155; 2)

38. Horani AC, Ulitski J

C, Kalish Y

C, Safadi R

PI. (2004). Hodgkin’s Disease in

Pregnancy. Isr Med Assoc J (IMAJ). 6:502-503. (0.879; 99/155; 1)


39. Mahamid MC, Mader R

PI, Safadi R

PI. (2011). Hepatotoxicity of tocilizumab and

anakinra in rheumatoid arthritis: management decisions. Clin Pharmacol. 3:39-43.

(X; X; 3)

40. Mahamid MC, Paz

C, Mader R

PI, Safadi R

PI. (2011). Hepatotoxicity due to

tocilizumab and anakinra in rheumatoid arthritis: two case reports. Int J Gen Med.

4:657-660. (X; X; 8)

41. Drori AC, Ribak Y

C, van Heerden PV

C, Meir K

C, Wolf D

C, Safadi R

PI. (2015).

Hemophagocytic lymphohistiocytosis due to acute primary herpes simplex virus 1

infection. J Clin Virol. 68:6-10. (2.647; 16/33; 0)

42. Safadi RPI

, Noviello SC, Boparai N

C, McPhee F

PI. (2016). Successful Retreatment of

Hepatitis C Genotype 1b Infection With Sofosbuvir + Simeprevir in a Patient With

Cirrhosis Who Had Prior Virologic Relapse After Treatment With Daclatasvir and

Asunaprevir. Clin Case Rep. 4(7):653-6. (X; X; 0)


, 2017

25

Letters (6):

1. Safadi RPI

, Sibirsky OC, Ben-Menahem I

C, Bar Ziv J

C, Ben-Yehuda A

PI. (1995).

Pneumoperitoneum in an older patient. J Am Geriatr Soc. 43:1-6. (3.842; 8/49; 1)

2. Safadi RPI

, Gafanovich IC, Rashkovski I

C, Kopilewitz B

C. (1996). Isolated external

jugular vein thrombosis in elderly. J Am Geriatr Soc. 44:885-886. (3.842; 8/49; 3)

3. Haviv YSC, Ben-Yehuda A

C, Poliac A

C, Safadi R

PI. (1997). Lymphoma and

systemic sclerosis - an uncommon association or possible coincidence with fatal

outcome. Eur J Haematol. 59:194-196. (2.544; 39/70; 6)

4. Haviv YSC, Osin P

C, Safadi R

PI. (1998). Accidental Isopropyl enema leading to

coma and death. Am J Gastroenterol. 93:850-851. (10.383; 6/79; 4)


C, Gilon D

PI. (1998). Patent ductus arteriosus in elderly. J Am

Geriatr Soc. 46:541-542. (3.842; 8/49; 2)

6. Safadi RPI

, Greenboim YC, Donchin M

PI. (2000). Impact of standard vaccination of

health care workers with hepatitis B vaccine on reducing the occupational risk of

infection. J Hosp Infect. 45:250-251. (2.655; 35/83; 0)


Reviews, commentaries, hypothesis, editorials (5):

1. Safadi RPI

, Almog YC, Dranitzki-Elhalel M

C, Rosenmann E

C, Tur-Kaspa R

PI.

(1998). Glomerulonephritis associated with acute hepatitis B virus infection. Rev

Ser Hepatitis. 1:6-7. (X; X; 0)

2. Albanis EC, Safadi R

C, Friedman SL

PI. (2003). Treatment of hepatic fibrosis: almost

there. Curr Gastroenterol Rep. 5:48-56. (X; X; 26)

3. Safadi RPI

, Friedman SLPI

. (2002). Hepatic fibrosis--role of hepatic stellate cell

activation. MedGenMed. 4(3):27. (X; X; 106)

4. Safadi RPI

. (2010). From Kitchen to GUT: Curcumin in Cholestasis (Commentary

manuscript requested by the editor). Gut. 59:565-566. (14.921; 2/79; 1)

5. Safadi RPI

(Invited to author panel by the EASL scientific committee). The EASL

Clinical Practice Guidelines in Hemochromatosis (2010), J Hepatol. 53(1):3-22.

(10.590; 5/79; 1)



, 2017

26

Multicenter studies (6):

1. McHutchison JPI

, Goodman ZC, Patel K

C, Makhlouf H

C, Rodriguez-Torres M

C,

Shiffman MC, Rockey D

C, Husa P

C, Chuang WL

C, Levine R

C, Jonas M

C, Theodore

DC, Brigandi R

C, Webster A

C, Schultz M

C, Watson H

C, Stancil B

C, Gardner S

PI;

Farglitizar Study InvestigatorsC (Angus P, Sievert W, Strasser S, Adams P,

Anderson F, Ghesquiere W, Heathcote EJ, Minuk G, Myers R, Husa P, Sperl J,

Urbánek P, Volfova M, Buggisch P, Dollinger M, Erhardt A, Gregor M, Herold C,

Manns M, Spengler U, Teuber G, Tillmann H, Lurie Y, Melzer E, Safadi RC, Tur-

Kaspa R, Veitsman E, Gane E, Rodriguez-Torres M, Streinu-Cercel A, Bogomolov

P, Nikitin I, Chow WC, Chuang WL, Lee CM, Lee SD, Sheen IS, Al-Osaimi A,

Altman R, Balistreri A, Bank L, Bloomer J, Boyer T, Brau N, Brown R Jr, Bzowej

N, Chung R, DeJesus E, Friedman S, Godofsky E, Hassanein T, Jonas M, Knapple

W, Kugelmas M, Kwo P, Lee W, Levine R, Lok A, Marsano L, McHutchison J,

Pauly M, Pockros P, Poordad F, Riley T, Rubin R, Rustgi V, Sherman K, Shiffman

M, Strauss R, Szabo G, Tatum H, Thuluvath P, Tsai N, Yoffe B, Saab S). Farglitazar

lacks antifibrotic activity in patients with chronic hepatitis C infection. (2010).

Gastroenterology. 138:1365-73. (18.187; 1/79; 45)

2. Nelson DRPI

, Benhamou YC, Chuang WL

C, Lawitz EJ


C,

Flisiak RC, Rasenack JW

C, Kryczka W

C, Lee CM

C, Bain VG

C, Pianko S

C, Patel K

C,

Cronin PWC, Pulkstenis E

C, Subramanian GM

C, McHutchison JG

PI; ACHIEVE-2/3

Study TeamC

(Silva M, Tanno T, Terg R, Angus P, Bell S, Cheng W, Crawford D,

George J, Harley H, Hughes B, Kronborg I, Lee A, Leggett B, Mollison L, Pianko S,

Roberts S, Sasadeusz J, Strasser S, Zekry A, Colle I, Delwaide J, Horsmans Y,

Langlet P, Michielsen P, Bailey R, Bain B, Cooper C, Heathcote J, Kaita K, Marotta

P, Sherman M, Swain M, Wong P, Yoshida E, Benhamou Y, Bourliere M,

Bronowicki JP, Causse X, Marcellin P, Pawlotsky JM, Poupon R, Trepo C, Berg T,

Eisenbach KC, Galle PR, Gerken G, Häussinger D, Manns M, Rasenack JW,

Zeuzem S, Sarin S, Shah SR, Baruch Y, Lurie Y, Safadi RC, Shouval D, Tur Kaspa

R, Abu Hassan MR, Tan SS, Shanmuganathan G, Muñoz Espinosa LE, Sanchez

Avila JF, Cianciara J, Flisiak R, Gladysz A, Horban A, Jablkowski M, Janczewska-

Kazek E, Kryczka W, Mach T, Lim SG, Tan CK, Teo EK, Yang WL, Cho M, Cho

SW, Han KH, Hwang SG, Jeong SH, Kim BH, Kweon YO, Lee KS, Lee HC, Paik

SW, Um SH, Yeon JE, Diago M, Esteban Mur R, Flamholc L, Hultcrantz R, Chang


, 2017

27

TT, Chao YC, Chuang WL, Hu CT, Kuo HT, Lai MY, Lee CM, Lin HH, Peng CY,

Sheen IS, Wu SS, Yang SS, Mahachai V, Pramoolsinsap C, Tanwandee T,

Thongsawat S, Foster G, Afdhal N, Arora S, Black M, Brau N, Brown R Jr, Bzowej

N, Davis G, Dickson R, Dieterich D, Everson G, Fried M, Gibas A, Gitlin N,

Harrison S, Herrine S, Jacobson I, Lambiase L, Lawitz E, Nelson D, Pockros P,

Reddy K, Rodriguez-Torres M, Rubin R, Rustgi V, Schiff E, Smith C, Sulkowski

M, van Leeuwen D, Vargas H). Albinterferon Alfa-2b was not inferior to pegylated

interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype

2 or 3. (2010). Gastroenterology. 139:1267-76. (18.187; 1/79; 48)

3. Zeuzem SPI

, Sulkowski MSC, Lawitz EJ

C, Rustgi VK


C, Bacon

BRC, Grigorescu M

C, Tice AD

C, Lurie Y

C, Cianciara J

C, Muir AJ

C, Cronin PW

C,

Pulkstenis EC, Subramanian GM

C, McHutchison JG

PI; ACHIEVE-1 Study Team

C

(Angus P, Bell S, Cheng W, Crawford D, George J, Harley H, Hughes B, Kronborg

I, Lee A, Leggett B, Mollison L, Pianko S, Roberts S, Sasadeusz J, Strasser S, Zekry

A, Ferenci P, Stauber R, Vogel W, Bailey R, Bain V, Cooper C, Heathcote J, Kaita

K, Marotta P, Peltekian K, Sherman M, Swain M, Wong P, Yoshida E, Dlouhy P,

Galský J, Husa P, Kumpel P, Plisek S, Rehak V, Urbanek P, Benhamou Y, Bourliere

M, Causse X, Couzigou P, Marcellin P, Pawlotsky JM, Poupon R, Trepo C, Berg T,

Eisenbach KC, Galle PR, Gerken G, Häussinger D, Manns M, Mauss S, Rasenack

JF, Reiser M, Wiegand J, Zeuzem S, Baruch Y, Lurie Y, Safadi RC, Shouval D, Tur

Kaspar R, Cianciara J, Flisiak R, Gladysz A, Horban A, Jablkowski M, Kryczka W,

Mach T, Calistru P, Grigorescu M, Manuc M, Stanciu C, Tanasescu C, Diago M,

Esteban Mur R, Forns X, Moreno R, Planas R, Cramp M, Foster G, Main J,

Mutimer D, Afdhal N, Arora S, Bacon B, Bennett M, Bernstein D, Brady C, Bzowej

N, Carp M, Chasen R, Davis G, Dickson R, Dieterich D, Everson G, Fallon M,

Flamm S, Franco J, Fried M, Galati J, Ghalib R, Gibas A, Gitlin N, Godofsky E,

Gordon S, Han S, Harrison S, Hassanein T, Herrine S, Herring R, Ho S, Jacobson I,

Jeffers L, Joshi S, Kugelmas M, Kwo P, Lambiase L, Lawitz E, Lee W, Lindsay K,

Liou I, Lucey M, Monsour H, Nelson D, Nyberg L, Phillips J, Pockros P, Poordad F,

Pruitt R, Reau N, Reddy KR, Rodriquez-Torres M, Rubin R, Rustgi V, Schiff E,

Schmidt W, Sheikh A, Sheikh M, Sherman K, Shiffman M, Sjogren M, Sulkowski

M, Terrault N, Tice A, Tong M, Vargas H, Wiesner R, Wruble L, Younossi Z).

Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized


, 2017

28

trial of patients with chronic hepatitis C virus genotype 1. (2010). Gastroenterology.

139:1257-66. (18.187; 1/79; 46)

4. Andus TPI

, Kocjan AC, Müser MC, Baranovsky AC, Mikhailova TLC, Zvyagintseva

TDC, Dorofeyev AEC, Lozynskyy YSC, Cascorbi IC, Stolte MC, Vieth M, Dilger

KC, Mohrbacher RC, Greinwald RPI

; on behalf of the International Salofalk

Suppository OD Study GroupMembers of the International Salofalk Suppository OD

Study Group (Eisenbach, Herold, Jongen, Kolbert, Chowers, Dotan, Eliakim,

Faszczyk, Konikoff, Lavy, Melzer, Niv, Safadi RC, Wardi, Bakulin, Belousova,

Golofeevsky, Grigorieva, Grinevich, Lakhin, Nikitin, Pavlenko, Simanenkov,

TkachenkoYourkov, Beresnitskiy, Golovchenko, Kharchenko, Zakharash,

Lehmacher W, Rogler G, Tromm A). (2010). Clinical trial: A novel high-dose 1 g

mesalamine suppository (salofalk) once daily is as efficacious as a 500-mg

suppository thrice daily in active ulcerative proctitis. Inflam Bowel Dis. 16:1947-56.

(4.358; 16/79; 13)


5. Jacobson IMPI

, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej

NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D,

Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL,

George S, Kauffman RS, Zeuzem SPI

; ADVANCE Study Team*. (2011). Telaprevir

for previously untreated chronic hepatitis C virus infection. N Engl J Med.

23;364(25):2405-16. *Gadano A, Terg R, Bell S, Cheng W, Crawford D, Dore G,

George J, MacDonald G, Roberts S, Ferenci P, Gschwantler M, Laferl H, Maieron

A, Heathcote J, Kaita K, Myers R, Sherman M, Yoshida E, Barange K, Couzigou P,

Marcellin P, Pawlotsky JM, Pol S, Serfaty L, Trépo C, Zarski JP, Berg T, Buggisch

P, Diepolder H, Goeser T, Mauss S, Rasenack J, Schmidt W, Wedemeyer H,

Zeuzem S, Baruch Y, Ben-Ari Z, Maor Y, Safadi RC, Shouval D, Zuckerman E,

Andreone P, Colombo M, Rizzetto M, Baka-Cwierz B, Flisiak R, Gladysz A,

Janczewska-Kazek E, Jablkowski M, Krycka W, Diago M, Esteban-Mur R,

Sanchez-Tapias J, Sola R, Brown A, Dusheiko G, Fox R, Afdhal N, Arora S,

Bennett M, Bernstein D, Bloomer J, Bochan M, Bonkovsky H, Brady C, Brown R,

Bzowej N, Cochran J, Chasen R, Davis G, De Jesus E, Di Bisceglie A, Dienstag J,

Dieterich D, Etzkorn K, Everson G, Fried M, Freilich B, Ghalib R, Gitlin N,

Godofsky E, Gordon S, Hassanein T, Jacobson I, Javadi F, Jonas M, Kilby A, Kwo


, 2017

29

P, Lawitz E, Lebovics E, Lee W, Luketic V, Maillard M, Monto A, Morgan T, Min

A, Murphy M, Nelson D, Northup P, Nyberg L, Pockros P, Poordad F, Poulos J,

Reddy R, Rodriguez-Torres M, Satyanarayana R, Schiff E, Schwartz H, Shaikh O,

Sheikh M, Sherman K, Smith J, Strohecker J, Sulkowski M, Szabo G, Te H,

Terrault N, Tsai N, Vargas H, Vierling J, Wruble L, Younossi Z, Zein N. (59.558;

1/155; 1541)

6. Manns MPPI

, Gane EPI

, Rodriguez-Torres MC, Stoehr A

C, Yeh CT

C, Marcellin P

C,

Wiedmann RTC, Hwang PM

C, Caro L

C, Barnard RJ

C, Lee AW

C; MK-7009 Protocol

007 Study Group (Baruch Y, Benhamou Y, Cave M, Davis G, Faruqui S, Fried M,

Godofsky E, Gschwantler M, Heim M, Lai MY, Lawitz E, Lurie Y, Moradpour D,

Müllhaupt B, Negro F, Pedersen C, Planas Vila R, Russo M, Safadi RC, Soza A,

Spengler U, Stauber R, Urbanek P, Volchkova E, Volfova M, Zeuzem S). (2012).

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve

patients with chronic hepatitis C: a randomized phase II study. Hepatology.

56(3):884-93. (11.711; 4/79; 33)

OTHER PUBLICATIONS (12): (instruction manuals, teaching aids etc.)

1. Safadi RPI

, Yossepowich OC, Ben-Yehuda A

PI. (1996). [Lactic acidosis and

Biguanides- review]. Harefuah. 130:280-283 [Hebrew]. (X; X; 0)

2. Safadi RPI

, Ashur YC, Ilan I

C, Shouval D

PI. (1996). Hepatitis C Virus infection and

primary mixed cryoglobulinemia-review. Harefuah. 130:833-836 [Hebrew]. (X; X;

0)

3. Blachar AC, Sosna J

C, Safadi R

C, Kopel L

C, Bar-Ziv J

PI. (1998). [Imaging in Liver

Transplantation - The 35-year revolution]. Harefuah. 135: 614-619 [Hebrew]. (X; X;

0)

4. Rowe MC, Safadi R

C, Ashur Y

C, Adler R

C, Shouval D

PI. (2001). Liver

transplantation and nursing care in Israel. Crit Care Nurs Q. 24:69-75. (X; X; 1)

5. Lieberman SC, Safadi R

C, Aner H

C, Verstandig A

C, Sasson T

C, Bloom AI

PI. (2002).

[Local thrombolysis for the treatment of patients with proximal deep vein

thrombosis of the leg]. Harefuah. 141:424-9, 499 [Hebrew]. (X; X; 3)

6. Shibolet OC, Safadi R

C, Ashur Y

C, Eid A

C, Ilan Y

PI. (2002). [Neurologic

complications following liver transplantation]. Harefuah. 141:30-3,127 [Hebrew].


, 2017

30

(X; X; 1)

7. Heyman SNPI

, Reches AC, Safadi R

C, Cohen R

PI. (2007). [Introduction of a brief

Problem-Based-Learning (PBL) experience in traditional medical faculty

curriculum]. Harefuah; 146:435-8, 502, 501 [Hebrew]. (X; X; 0)

8. Safadi RPI

. (2008) [Is Cirrhosis Revisable?] Medicine (HaRefuah?) ; 1:20-23

(Invited Review by Editor), [Hebrew]. (X; X; 0)

9. Mizrahi MC, Lalazar G

C, Horwich Y

C, Adar T

C, Safadi R

PI. (2008). [Benign

recurrent intrahepatic cholestasis type-II--a rare cause of direct hyperbilirubinemia

exacerbations with hepatic fibrosis]. Harefuah. 147:381-3, 480 [Hebrew]. (X; X; 1)


10. Sikuler E, Ackerman Z, Braun M, Baruch Y, Bruck R, Safadi R, Shlomai A, Ben-

Ari Z; Israeli Association for the Study of the Liver. (2012). [Guidelines for

diagnosis and management of cirrhotic ascites and its complications. The Israeli

Association for the Study of the Liver]. Harefuah. 151: 705-8, 719. [Hebrew]. (X; X;

1)

11. Zuckerman E, Safadi R, Oren R, Shibolet O, Baruch Y, Bruck R, Lurei Y, Kaspa

RT, Abu-Mouch S, Shouval D, Ben-Ari Z; (2012). [Israeli guidelines for the

treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of

the Liver]. Harefuah. 151:709-14, 719. [Hebrew]. (X; X; 1)

12. Michaiel RPI

, Calderon M.RC, Shteyer E

C, Ashur Y

C, Safadi R

PI. (2012). [Vertical

HBV transmission in Jerusalem within the vaccine era]. Harefuah. 151:671-4, 722,

721. [Hebrew]. (X; X; 0)


, 2017

31

Original Papers in Non-Peer Reviewed Journals (20):

1. Safadi RPI

, Shouval DC, Ashur Y

C, Eid A

C, Jurim O

C, Livni N

T, Galun E

PI. (1997).

Natural history of HCV viremia following liver transplantation and clinical coarse of

re-infection. Transplant Proc. 29:2635-2639. (0.867; 145/151; 151/200; 24/25; 0)

2. Safadi RPI

, Eid AC, Ilan Y

C, Ashur Y

C, Jurim O

C, Shouval D

PI. (1997). Natural

history of de novo hepatitis B virus infection in liver transplantation recipients.

Transplant Proc. 29:2677-2679. (0.867; 145/151; 151/200; 24/25; 4)

3. Safadi RPI

, Eid AC, Ilan Y

C, Ashur Y

C, Jurim O

C, Shouval D

PI. (1997). Should

hepatitis B immunoglobulin therapy be discontinued after HBV re infection

following liver transplantation? Transplant Proc. 29:2680-2683. (0.867; 145/151;

151/200; 24/25; 1)

4. Safadi RPI

, Eid AC, Ilan Y

C, Tur-Kaspa R

C, Jurim O

C, Shouval D

PI. (1997).

Hepatitis C associated cryoglobulinemia post liver transplantation. Transplant Proc.

29:2684-2686. (0.867; 145/151; 151/200; 24/25; 4)

5. Eid AC, Zamir G

C, Ilan Y

C, Galun E

C, Safadi R

C, Schaaps T

C, Berlatzky Y

C,

Shouval DC Jurim O

PI. (1998). Liver transplantation across the ABO barrier: the role

of plasmapheresis. Transplant Proc. 30:701-703. (0.867; 145/151; 151/200; 24/25;

10)

6. Safadi RPI

, Ilan YC, Eid A

C, Galun E

C, Ashur Y

C, Goldin E

C, Papo O

C, Blachar A

C,

Jurim OPI

. (1999). Solid tumors after liver transplantation. Transplant Proc. 31:1894-

1895. (0.867; 145/151; 151/200; 24/25; 9)

7. Safadi RPI

, Eid AC, Ilan Y

C, Goldin E

C, Shouval D

C, Wengrower D

C, Blachar A

C,

Libbson EC, Verstandig A

C, Ashur Y

C, Jurim O

PI. (1999). The role of ERCP in

biliary complications after liver transplantation. Transplant Proc. 31:1897-1898.

(0.867; 145/151; 151/200; 24/25; 2)

8. Safadi RPI

, Ilan YC, Galun E

C, Ashur Y

C, Goldin E

C, Pappo O

C, Jurim O

C, Blachar

AC, Eid A

PI. (1999). Primary Sclerosing Cholangitis and liver transplantation.

Transplant Proc. 31:1896. 0.511;17/17;0. (0.867; 145/151; 151/200; 24/25; 2)

9. Safadi RPI

, Ilan YC, Jurim O

C, Schenker J

C, Galun E

C, Ashur Y

C, Eid A

PI. (1999).

Pregnancy after liver transplantation. Transplant Proc. 31:1899-1900. (0.867;

145/151; 151/200; 24/25; 5)

10. Eid AC, Lyass S

C, Venturero M

C, Ilan Y

C, Safadi R

C, Zamir G

C, Berlatzky Y

C,

Jurim OPI

. (1999). Vascular complications post orthotopic liver transplantation.


, 2017

32

Transplant Proc. 31:1903-1904. (0.867; 145/151; 151/200; 24/25; 9)

11. Lyass SC, Venturero M

C, Ilan Y

C, Safadi R

C, Zamir G

C, Jurim O

C, Berlatzky Y

C,

Eid API

. (1999). Reoperation after liver transplantation. Transplant Proc. 31:1901-

1902. (0.867; 145/151; 151/200; 24/25; 2)

12. Israeli EC, Eid A

C, Ilan Y

C, Adler R

C, Galun E

C, Ashur Y

C, Jurim O, Safadi R

PI.

(2000). The course of Hepatitis B Virus after liver transplantation. Transplant Proc.

32:711. (0.867; 145/151; 151/200; 24/25; 0)

13. Rudis RC, Rudis E

C, Lupo Y

C, Safady R

C, BonneO

PI. (2000). Psychosocial model

for evaluation and intervention with candidates for organ transplantation. Transplant

Proc. 32:761-762. (0.867; 145/151; 151/200; 24/25; 2)

14. Bishara AC, Brautbar C

C, Eid A

C, Sherman L

T, Safadi R

PI. (2001). Killer inhibitory

receptor mismatching and liver transplantation outcome. Transplant Proc. 33:2908.

(0.867; 145/151; 151/200; 24/25; 6)

15. Shibolet OC, Galun E

C, Bishara A

C, Eid A

C, Birmanns B

C, Ilan Y

C, Safadi R

PI.

(2001). Major neurological complications following liver transplantation. Transplant

Proc. 33:2959. (0.867; 145/151; 151/200; 24/25; 5)

16. Israeli EC, Galun E

C, Eid A

C, Ilan Y

C, Ashur Y

C, Jurim O

C, Bishara A

C, Safadi R

PI.

(2001). Combination therapy for hepatitis C virus reinfection after orthoptic liver

transplantation. Transplant Proc. 33:2929. (0.867; 145/151; 151/200; 24/25; 3)

17. Safadi RPI

, Galun EC, Ashur Y

C, Eid A

C, Melhem A

C, Jurim O

C, Polak R

C, Ilan Y

PI.

(2001). Bone mineral density after liver transplantation. Transplant Proc. 33:2950.

(0.867; 145/151; 151/200; 24/25; 0)

18. Kolker OC, Galun E

C, Melhem A

C, Ilan Y

C, Eid A

C, Jurim O

C, Ashun Y

C, Safadi

RPI

. (2001). Primary biliary cirrhosis and liver transplantation. Transplant Proc.

33:2932. (0.867; 145/151; 151/200; 24/25; 0)

19. Menachem YC, Safadi R

PI, Ashur Y

C, Eid A

C, Jurim O

C, Ilan Y

PI. (2001). Pre-

malignant conditions: risk factor for post liver transplantation malignancy.

Transplant Proc. 33:2935-6. (0.867; 145/151; 151/200; 24/25; 1)


C, Kalish Y

C, Safadi R

C, Ashur Y

C, Eid A

C, Shouval D

C, Wolf

DPI

. (2003). Late cytomegalovirus infection occurring two or more years following

liver transplantation: a report of seven cases and review of the literature. Transplant

Proc. 35(2):663-4 (0.867; 145/151; 151/200; 24/25; 4)



, 2017

33

Patents:

1. "MODULATION OF NLGN4 EXPRESSION, NK CELL ACTIVITY IN NON-

ALCOHOLIC FATTY LIVER DISEASE (NAFLD)". Patent No. 9,243,294.

Granted at Jan 26, 2016

2. "MODULATION OF NLGN4 EXPRESSION, NK CELL ACTIVITY IN NON-

ALCOHOLIC FATTY LIVER DISEASE (NAFLD)". Patent No. 14/963,319. Notice

of Allowance from 03/06/2016

3. INHIBITORS OF NEUROLIGIN 4 – NEUREXIN 1-BETA PROTEIN-PROTEIN

INTERACTION FOR TREATMENT OF LIVER DISORDERS. Patent No.

PCT/IL2016/050351. PCT, was filed at 31/03/2016



, 2017

34

CONFERENCES:

Invited lectures

More than 200 invited lectures and chairman within the Hepatology field in regional and

international meetings as well as advisory boards. Nemours lectures in local meetings

focusing on Viral hepatitis & Fatty liver disease. Among Them:

1. Organizer and Chair of the upcoming The International Conference on Fatty

Liver, Seville, Spain June 1-3, 2017

2. Treatment of Non-Alcoholic Steatohepatitis (NASH): The Present and the

Future. The 17th Annual Educational Meeting in Gastroenterology.An

Accreditation Council for Continuing Medical Education (ACCME) accredited

continuing medical education (CME) activity. Cedars-Sinai Harvey Morse

Auditorium, Los Angeles, CA, USA. March 3rd

-4th

2017.

3. HCV EASL & AASLD Guidelines. Innovations in Gastroenterology, Israeli

Gastroenterology and Liver Disease Society. January 31st, 2017.

4. Hepatic Encephalopathy. Pre Exam Course for Gastroenterology Fellows, Israeli

Gastroenterology and Liver Disease Society. Sheba Medical center 5/12/2016.

5. HCV in Pregnancy. Gynecology & Obstrictive Forum, Sheba Medical Center

02/12/2016.

6. Treating HCV patients with new DAAs. AbbVie Negev Congress for PCPs Southe

of Israel, Beer Sheba, 1/10/2016

7. Treating HCV patients with new DAAs. AbbVie North Congress for PCPs

Nazareth North of Israel, 24/8/2016

8. Liver Viruses: From A to E. The Future with Abbot Molecular. Tel Aviv, 01/6/2016

9. The Liver in Thalassemia – Hepatitis B & C and cirrhosis. Novartis 6th

meeting on

hemoglobinopathies. Ramat Gan, 30/3/2016

10. Anti Virals & HCC. HCC Meeting: Screening, Imaging & Therapy. The Israel

Association for the Study of Liver, Tel Aviv, 29/3/2016

11. Granulomatous Hepatitis: Israel Gastroenterology Association Annual Meeting. Tel

Aviv, 3-5/2/2016

12. NK Cell Therapy. The Liver Fibrosis SIG program, Antifibrotic Strategies at

the Brink of Translation, 13/11/2015, American Association for the Study of

Liver Diseases, The Liver Meeting® in San Francisco.

13. Update in Viral hepatitis & Fatty Liver Disease. Invited by Prof. Mario Pirisi,

University of Eastern Piedmont "Amedeo Avogadro", Novara, Italy 5/12/2014.

14. HCV Update (Introduction). Viral Hepatitis Cure & Beyond Meeting, The Israel

Association for the Study of Liver, Tel Aviv, 13/10/2015

15. HBV Vertical Transmission: The Real Life. Treatment of Viral Hepatitis Meeting.

The Israel Association for the Study of Liver, Eilat, 12-14/6/2014

16. Primary Screlosing Cholangitis & Inflammatory Bowel Diseases, Invited Review

Lecture, The Gastroenterology IBD forum, 29/4/2014

17. Hepatic Encephalopathy (HE): Lactulose, Probiotics, LoLa or Rifaximin therapy?,

Invited Review Lecture, The October meeting of the Israel Association for the Study

of Liver, 8/10/2013, Tel Aviv

18. Update in HCC, 27/3/2012, Invited by General Doctors, Nazareth

19. Update in HCC, 4/2/2014, Invited by General Doctors, Jerusalem


, 2017

35

20. Evidence based integration of SIRT into HCC management, 11/5/2014, Advisory

Board, Medison, Tel Aviv.

21. Prevention of HCC in HCV, Invited Review Lecture, The March meeting of the

Israel Association for the Study of Liver, 8/3/2013

22. Update in Liver Diseases. Jerusalem, Hadassah, Maldovian Physician Forum

27/2/2012.

23. Lessons in Fatty Liver Disease. Beir-Sheba, Family Physician Forum 15/2/2012

24. HBV & Pregnancy. Nazareth, Gynecologists Forum 17/1/2012

25. Update Viral Hepatitis B. Jerusalem, Pharmacists Forum 11/1/2012

26. Update Viral Hepatitis:.Nazareth, Dentist Forum 16/12/2011

27.

28. Afula, Family Physician Forum 23/11/2011: Update NASH.

29. Jerusalem, Maccabi Forum 6/10/2011: Update in Viral Hepatitis.

30. Nazareth, The Arabic Health Forum 29/6/2011: Update in Hepatocellular

Carcinoma.

31. Nazareth, The Arabic Health Forum 29/6/2011: Is Cirrhosis Reversible?

32. Ha-Emique, Afula, The Gynecology & Obstetrics Forum 29/6/2011: Viral hepatitis

In Pregnancy.

33. Petach Tiqua, The Roche Company Team 21/6/2011: Update in HBV.

34. The Bayer Company Team 13/6/2011: Update in Hepatocellular Carcinoma.

35. Belinson Hospital, Gastroenterology Physician Forum 17/5/2011: Liver Thrombotic

Events.

36. Afula, The North General Physician Forum 23/3/2011: Viral hepatitis Update.

37. Immune Suppression in Liver Transplantation. Transplantation Meeting of Surgery-

B Department. Hadassah Medical Center 2/3/2011.

38. Seminar, Immune Modulation of Hepatic Fibrosis. Gene Therapy Seminars,

Hadassah Medical Center 24/3/2011.

39. Chairman of Parallel Session in the annual meeting, European Association for the

Study of Liver, Berlin 31/3/2011 to 3/4/2011.

40. Chairman of Parallel Session in the annual meeting, Israel Gastroenterological

Association, Eilat 26-28/1/2011.

41. Nazareth, Leumit Forum 17/1/2011: Viral hepatitis Update.


42. Beir Sheva, General Family Doctors Forum 15/12/2010: Viral hepatitis Update.

43. Maalot, General Family Doctors Forum 10/12/2010: Viral hepatitis B infection: a

new therapeutic era.

44. Nazareth, Clalit Forum 10/11/2010: Viral hepatitis Update.

45. Nazareth, Holy Family Forum 30/7/2010: Viral hepatitis Update.

46. Jerusalem, Biotes Ltd. Forum 27/7/2010: Viral hepatitis B Update.

47. Jerusalem, Meuhedet Forum 14/7/2010: Viral hepatitis Update.

48. Nazareth Hospital Forum 25/6/2010: Update in Viral hepatitis.

49. Rivka Ziev Liver Meeting, 13/5/2010: Update on Hepatic Fibrosis.

50. Ramallah, The First GI conference in Palestine 20-22/5/2010: HBV current

treatment guidelines.

51. Ramallah, The First GI conference in Palestine 20-22/5/2010: HCV: epidemiology

and Natural History.

52. Ramallah, The First GI conference in Palestine 20-22/5/2010: The role of HBSAg

level in HBV treatment (symposium).


, 2017

36

53. Ramallah, The First GI conference in Palestine 20-22/5/2010: Current guidelines in

management of Ascites.

54. Nazareth meeting for The Liver Diseases Day, 9/6/2010: Is cirrhosis Reversible?

55. Nazareth, “The health status of Arabic population along time axis”, 5/5/2010: Viral

hepatitis Update

56. Jerusalem meeting for The Liver Diseases Day, 24/3/2010: Chronic hepatitis B.

57. Immune Modulation of hepatic fibrosis; on 2/3/2010, Hannover Seminar,

invited by Prof. Heiner Wedemeyer. Department of Gastroenterology,

Hepatology & Endocrinology. Medizinische Hochschuel Hannover, Hannover,

Germany.

58. Hepatitis B Virus Infection Clinical Practice Guidelines; on 19/1/2010, Ma’alie

Hamisha, Jerusalem, invited by Prof. Gil Lievovitz, HUG of Internal Medicine,

Hebrew University, School of Medicine.

59. Pivotal effects of Toll-like receptor-9 activation in hepatic fibrosis; on 21/1/2010,

Gene Therapy Seminar, invited by Prof. Eithan Galun, Gene Therapy, Hadassah

Medical Center.

60. Hepatitis B Virus Infection; on 18/12/09, Eilat, invited by organizers of “Early

screening in community: reality versus challenges” meeting for physicians.

61. Hepatitis B Virus Infection; on 13/12/09, Galilee, invited by Kopat Holim Clalit for

physicians.

62. Hepatitis B Virus Infection; on 4/11/09, Nazareth, invited by organizers of “The

health status of Arabic population along time axis”.

63. Should Lamivudine/ Hepsera be switched to new NUC’s before evolving of

mutants? On 13/10/09, Tel-Aviv, invited by organizers of “Israeli Association for

the Study of Liver” as part of local clinical practice guidelines in HBV treatment.

64. Chairman of Parallel Session in Non Alcoholic Steato Hepatitis and Hepatitis C

Infection; on 8/9/09, Israeli Association for the Study of Liver Bi-annual meeting,

Tel-Aviv.

65. Hepatitis B Virus Infection; on 21/7/09, Petach Tiquva, invited by GSK organizers

for GSK team.

66. Hepatic Fibrosis: Potential Therapeutic Options; on 17/6/09, Eilat, invited by the

Israeli Association for Gastroenterology and Liver Diseases.

67. Chairman of Parallel Session in Viral Hepatitis Immunology; on 25/4/09, The EASL

annual meeting, Copenhagen. Invited by The European Association for the Study of

the Liver.

68. Chairman of Parallel EASL/ISHEN (EASL & International Society of Hepatic

Encyphalopathy and Hydrogen metabolism) Joint Workshop; on 22/4/09, The EASL


the Liver.

69. Early Morning Workshop, Innate immunity in liver disease; on 24/4/09, The EASL


the Liver.

70. Viral Hepatitis in Thalassemia; on 25/5/08, City Tower, Tel Aviv, invited by The

Israeli Association of Thalassemia and/or Sickle Cell Anemia.

71. The anti cancer effects of hepatic stellate cells; on 28/4/08, Tel Aviv, invited by the

Italian-Israeli Forum on Science and Technology, David Intercontinental, Tel Aviv.

72. Chairman of Parallel Session in Hepatitis C Immunology; on 26/4/08, The EASL

annual meeting, Milan. Invited by The European Association for the Study of the

Liver.


, 2017

37

73. Early Morning Workshop, Basic Mechanism of Fibrosis; on 25/4/08, The EASL

annual meeting, Milan. Invited by The European Association for the Study of the

Liver.

74. New therapies in Viral Hepatitis C; on 9/4/08, Nazareth, invited by the Maccabi

HMO.

75. Hepatitis B/C Virus Recurrence after liver transplantation; on 22/2/08, Tiberias,

invited by the Israeli Society for Organ Transplantation.

76. Liver transplantation: Whom & When? For GIT residents on 19/10/07, in Kasseri,

invited By the Israeli Association for Liver Diseases.

77. Pathogenesis of Hepatic Sarcoidosis; on 3/9/07, in Hetzlia, invited By the Israeli

Association for Liver Diseases.

78. New Strategies in the management Viral Hepatitis B; on 3/5/07, in Natania, invited

by By Quintile Company.

79. Liver in Pregnancy; on 18/5/07, for the Gynecology and Obstetrics’ Jerusalem

Society, Givaat Ram, Jerusalem.

80. Occupational HCV or HBV Infection in Gastroenterology; on 23/3/07, in Tiberias,

invited By the Israeli Association for Liver Diseases.

81. Protocol Mechanics: The Fundamentals of International Clinical Research

Workshop; on 9/3/07, City Tower, Tel Aviv, invited by Schering Plough Company.

82. Hepatic Fibrosis; on 7/11/06, Basic Science Forum, Division of Medicine,

Hadassah, invited By Dr. Y. Haviv.

83. Hepatic Fibrosis; on 18/5/06, in the Internal Medicine Department, Hadassah,

Mount Scopus, invited By Prof. Tova Chachek.

84. Liver Diseases & Dental Manifestations; on 2/2/06, for the Dentists and Oro

Mandibular Surgeons, Hadassah, Jerusalem.

85. Hepatic Fibrosis; on 15/11/05, in the Gastroenterology Unit, Bilinson, invited By

Prof. Yaron Niv.

86. Viral Hepatitis; For Internal medicine residents on 29/6/05, in Division of Medicine,

invited By Division of Medicine.

87. Treatment of Hepatic Fibrosis; For GIT residents on 15/6/05, in Tiberias, invited By

the Israeli Association for Liver Diseases.

88. Viral Hepatitis; For GIT residents on 9/6/05, in Gastroenterology Unit, invited By

Prof Ligumsky.

89. Viral Hepatitis; on 28/3/05, in Microbiology Department, invited By Prof Mosis.

90. Beneficial effect of glatiramer acetate in Immune Modulation of Hepatic Fibrosis;

on 26/10/04, in Teva Company, Matania, invited By Ilana Path, Teva Company.

91. Immune Modulation of Hepatic Fibrosis; on 11/10/04, in gene Therapy Institution,

Hadassah, invited By Prof. Eithan Galun.

92. NASH: Weight loss, lifestyle modifications and drugs; on 20/9/04, NASH meeting,

Hertzlia, invited by the Israeli Association for Liver Diseases.

93. Auto Immune Hepatitis and PBC; For GIT residents; on 9/9/04, in Haifa, invited By

the Israeli Association for Liver Diseases.


, 2017

38

Oral Presentations:

1. Safadi R, Eid A, Shouval D, Ilan Y, Ashur Y, Tur-Kaspa R, Galun E and Jurim O.

Benign course of de novo hepatitis B virus infection in liver transplantation

recipients. Israel Transplantation Society, 1997.

2. Safadi R, Eid A, Shouval D, Ilan Y, Ashur Y, Livni N, Galun E and Jurim O.

Natural history of HCV viremia and clinical coarse of re-infection following liver

transplantation. Israel Transplantation Society, 1997.

3. Safadi R, Eid A, Shouval D, Ilan I, Ashur Y, Tur-Kaspa R, Galun E and Jurim O.

Beneficial effect of Ribavirin on hepatitis C associated cryoglobulinemia post liver

transplantation. Israel Transplantation Society, 1997.


Long term hepatitis B virus immunoglobulin therapy for HBV re infection following

liver transplantation. Israel Transplantation Society, 1997.

5. Shibolet O, Galun E, Eid A, Birmanns B, Ilan Y, and Safadi R. Major neurologic

complications following liver transplantation. Israel Transplantation Society, 2000.

6. Israeli E, Ilan Y, Galun E, Ashur Y, Eid A, Jurim O and Safadi R. The beneficial

effect of combination therapy for HCV re infection after liver transplantation. Israel

Transplantation Society, 2000.

7. Safadi R, Galun E, Ashur Y, Eid A, Jurim O, Polak R and Ilan Y. Bone mineral

density following liver transplantation. Israel Transplantation Society, 2000.

8. Kolker O, Ilan Y, Galun E, Eid A, Jurim O, Ashur Y, and Safadi R. Primary biliary

cirrhosis and liver transplantation. Israel Transplantation Society, 2000.

9. Menachem Y, Safadi R, Ashur Y, Eid A, Jurim O, and Ilan Y. Pre-malignant

conditions: a risk factor for post liver transplantation malignancy. Israel


10. Bishara A, Eid A, Sherman L, Brautbar H and Safadi R. Killer inhibitory receptors

(KIR) mismatching and liver transplantation outcome. Israel Transplantation

Society, 2000.

11. Safadi R, Kogan J, Abo-Mouch S, Ilan Y, Galun E, Ashur Y, and Shouval D.

Fulminant hepatitis in Israel. Israel Transplantation Society, 2000.

12. Safadi R, Ilan Y, Eid A, Jurim O, Galun E, Ashur Y, Rowe M and Shouval D.

Follow up of 170 patients after liver transplantation in Jerusalem. , Israel



, 2017

39

13. Adoptive Transfer of Hepatic Fibrosis by Lymphocytes from Mice with CCl4 Liver

Injury – Implications for the Role of the Immune System in Disease Pathogenesis.

Rifaat Safadi, Carlos E. Alvarez, Michael P. Cooreman, Francis Eng and Scott L.

Friedman. Oral Presentation, AASLD, Boston 2002.

14. Melhem A, Alvarez CE, Ilan Y, Bishara A, Friedman SL and Safadi R. Anti-fibrotic

Activity of NK cells in Experimental Liver Injury through Enhanced Activation

Combined with Increased Susceptibility of Activated HSC’s to Killing. Oral

Presentation, AASLD, Boston 2003.

15. Horani A, Melhem A, El-Haj M, Doron S, Alvarez CE, Friedman SL, Ilan Y and

Safadi R. Beneficial effect of glatiramer acetate in Immune Modulation of Hepatic

Fibrosis. Oral Presentation, Israeli Association for the Study of Liver, Eilat 2004.

16. Higazi AAR, El Haj M, Melhem A, Horani A, Doron S, Alvarez CE, Friedman SL,

Ilan Y and Safadi R. Immune Modulator effects of Plasminogen Activators on

Hepatic Fibrogenesis. Oral Presentation, Israeli Association for the Study of Liver,

Eilat 2004.

17. Ulitzky J, Horani A, Bishara A, Saliba M, Safadi R. Immunoprophylaxis by

Lamivudine in pregnancy. Oral Presentation, Israeli Association for the Study of

Liver, Eilat 2004.

18. Gur C, Karussis D, Alper R, Golden E, Ilan Y and Safadi R. The use of Glatiramer

acetate as immune modulator therapy in animal model of Colitis. Oral

Presentation, American Gastroenterology Association annual meeting, 2004.

19. Horani A, Melhem A, El-Haj M, Doron S, Alvarez CE, Friedman SL, Ilan Y and

Safadi R. Beneficial effect of glatiramer acetate in Immune Modulation of Hepatic

Fibrosis. Oral Presentation, AASLD, Boston 2004.

20. El-Haj M, Bishra A and Safadi R. HLA frequencies observed in HBV clearance

resemble those of HBV vaccine. Oral Presentation, Israeli Association for the

Study of Liver, Eilat 2005.

21. Abu-Fanna R, Nawadha R, Ghantous R, Shalata A, Hourani A, Barhoum M and

Safadi R. High HBV vertical transmission in spite universal vaccination in the

Arabic population. Oral Presentation, Israeli Association for the Study of Liver,

Eilat 2005.

22. Muhanna N, Bishra A, Doron S and Safadi R. Activated but not normal


, 2017

40

lymphocytes undergo endocytosis inside Human hepatic stellate cells. Oral

Presentation, Israeli Association for the Study of Liver, Eilat 2005.

23. Muhanna N, Doron S, Wald O, Bishra A and Safadi R. Human hepatic stellate cells

show features of antigen-presenting cells with a direct adhesion with lymphocytes.

Oral Presentation, Israeli Association for the Study of Liver, Eilat 2005.

24. Bishra A, Horani A, Brautbar C, Zamir G, Eid A O, and Safadi R. Killer Inhibitory

Receptors Mismatching and Liver Transplantation Outcome. Oral Presentation,

Israeli Association for the Study of Liver, Eilat 2005.

25. Muhanna N, Bishra A, Doron S and Safadi R. Human hepatic stellate cells show

features of antigen-presenting cells with a direct adhesion with lymphocytes. Oral

Presentation, Israeli Association of Gastroenterology, Dead Sea, 2005.

26. Safadi R, Zigmond E, Shalev Z, Horan A, Pappo O, Engelhardt D, Rabbani E and

Ilan Y. Glucocerebroside treatment ameliorates hepatic fibrosis by inhibition of

NKT lymphocytes. Israeli Association for the Study of Liver, Eilat 2006.

27. Abu-Mouch S, Garra J, Sharkia M, Abu-Fanna R, Rothbart H, Ghantous R, Doron

S, Trabelsi S, Hourani A and Safadi R. HBV epidemiology in the Arabic

population. Israeli Association for the Study of Liver, Eilat 2006.

28. Muhanna N, Doron S, Trabelsi S and Safadi R. siRNAs for Anti-fibrotic Activity in

Liver Disease. Israeli Association for the Study of Liver, Eilat 2006.

29. Muhanna N, Doron S, Trabelsi S and Safadi R. Lymphocytes modulate in-vitro anti

tumor effect of hepatic stellate cells towards HEPB3 cells by phagocytosis. Israeli

Association for the Study of Liver, Eilat 2006.

30. Muhanna N, Azzeh M, Doron S, Trabelsi S and Safadi R. Knock down of NK

related Killing Immunoglobulin receptors decrease hepatic fibrosis. Oral

Presentation, EASL annual meeting, Milan, 2008.

31. Avraham Y, Doron S, Amer J, Muhanna N, Abu-Tir L, Schneider R, Berry E.M,

Safadi R. CB2 cannabinoid receptor affects hepatic fibrosis via lymphocyte

alterations and HSC phagocytosis. Oral Presentation, EASL annual meeting,

Copenhagen, 2009.

32. Yun-Fan Liaw, Ting-Tsung Chang, Shun-Sheng Wu, Eugene R. Schiff, Kwang-

Hyub Han, Ching-Lung Lai, Rifaat Safadi, Samuel S. Lee, Waldemar Halota,

Zachary D. Goodman, Hui Zhang, Robert Hindes, Uchenna Iloeje, Suzanne Beebe,


, 2017

41

Bruce Kreter. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis

and continued histologic improvement in patients with HBeAg(+) and (-) chronic

hepatitis B: Results from studies ETV-022, -027 and -901. Oral Presentation, Bi-

Annual meeting of the Israel Association for Gastroenterology and Liver Diseases,

Tel-Aviv, 2009.

33. J. Amer, S. Doron, L. Abu Tair, R. Safadi. Differentiation of hepatic-stellate-cells

to 4 sub-populations following phagocytosis of lymphocytes. Oral Presentation.

Israel Gastroenterological Association, Tel-Aviv 22/6/2010.

34. K. Abed, L. Abu Tair, J. Amer, S. Doron, Muhanna N, R. Safadi. Adoptive-transfer

of liver injury and regeneration using Parabiosis-system. Oral Presentation. Israel

Gastroenterological Association, Tel-Aviv 22/6/2010.

35. Jonathan H. Axelrod, Johnny Amer, Elena Khvalevsky, Sarit Doron, Lina Abu Tair,

Yael Nechemia, Orit Pappo, Eithan Galun, & Rifaat Safadi. Pivotal effects of Toll-

like receptor-9 activation in hepatic fibrosis. Oral Presentation, EASL annual

meeting, Vienna, 2010.


36. Lina Abu-Tair, Johnny Amer, Sarit Doron, Nidal Muhanna, Rifaat Safadi. Leptin &

Adiponectin immune modulation in hepatic fibrosis via HSC phagocytosis of

lymphocytes. Oral Presentation. Annual meeting of the Israel Association for

Gastroenterology and Liver Diseases & Israel Gastroenterological Association, Eilat

2011.

37. Lina Abu-Tair, Sarit Doron, Johnny Amer, Mahmoud Mahamid, Saif Abu-Mouch &

Rifaat Safadi. Anti- Fibrotic Immune-modulation effects of 25-Hydroxy-Vitamin D

in HCV and mice fibrosis model. Oral Presentation. Annual meeting of the Israel

Association for Gastroenterology and Liver Diseases & Israel Gastroenterological

Association, Eilat 2011.

38. Lina Abu-Tair, Sarit Doron, Johnny Amer, Mahmoud Mahamid, Saif Abu-Mouch,

Rifaat Safadi. Anti- Fibrotic Immune-modulation effects of 25-Hydroxy-Vitamin D

in HCV and mice fibrosis model. Oral Presentation. EASL annual meeting, Berlin,

2011.

39. Johnny Amer, Rami Grifat, Lina Abu-Tair, Sarit Doron, Rifaat Safadi. The pro-

fibrotic effects of pregnancy in a hepatic fibrosis mice model. Oral Presentation.

EASL Monothematic Conference "Liver Fibrogenesis: Common and Organ Specific


, 2017

42

Mechanisms" Petersberg, June 17-18, 2011.

40. Johhny Amer, Sarit Doron, Lina Abu-Tair, Rifaat Safadi. The immune modulation

roles of NK cells in mice model of Non Alcoholic Fatty Liver Disease. Oral

Presentation. Annual meeting of the Israel Association for Gastroenterology and

Liver Diseases & Israel Gastroenterological Association, Eilat 2012.

41. M. Adileh, Y. Azraq, Z. Bahouth, S. Abu-Gazaleh, G. Zamir, G. Almogi, A.

Rivkind, A. Khalaileh, Rifaat Safadi. Simple non-invasive predictors for the

outcome of bile duct stones. Oral Presentation. Annual meeting of the Israel

Association for Gastroenterology and Liver Diseases & Israel Gastroenterological

Association, Eilat 2012.

42. Mahamid Mahmud, Ibrahim Abdullah, Rami Ghantous, Johnny Amer, Sarit Doron

and Rifaat Safadi. Low Vitamin D levels in Nonalcoholic Fatty Liver Disease

associate with Insulin resistance and Liver Injury progression via immune NK

mechanism. Oral Presentation. Israeli Association for the Study of Liver, Kfar

Blum 2012.

43. Johnny Amer, Rami Grifat, Lina Abu-Tair, Sarit Doron, Areej El Khatib, Carmel

Kasher, Rifaat Safadi. The pro-fibrotic effects of pregnancy in a hepatic fibrosis

mice model. Oral Presentation. Israeli Association for the Study of Liver, Kfar

Blum 2012.

44. Amal Bishara, Ola Haj-Yehya-Abu-Aita, Johnny Amer & Rifaat Safadi. HLA-C

matching with liver transplantation outcome suggest NK role via HLA-Cw*

alloantigen. Oral Presentation. Israeli Association for the Study of Liver, Kfar

Blum 2012.

45. Nizar Saed, Marwan Hakim, Youssef Nijim, Nikola Farah, Jeryes Jamalia, Tawfik

Nuser, Kher Ismael, Rami Ghantous, Johnny Amer, Rifaat Safadi. Sci-B-Vac is

superior to Engerix-B for preventing HBV vertical transmission. Oral

Presentation. EASL annual meeting, London, 2014.

46. Johnny Amer, Sarit Doron, Ahmad Salhab, Nadav Ilani, Rifaat Safadi.

Homozygous NLG4-/-

(KO) mice show a decreased inflammatory and fibrotic

profile and are associated with NK cells increased killing activity. Oral

Presentation. EASL annual meeting, London, 2014.

47. Nizar Saed, Marwan Hakim, Youssef Nijim, Nikola Farah, Jeryes Jamalia, Tawfik


, 2017

43

Nuser, Kher Ismael, Rami Ghantous, Johnny Amer, Rifaat Safadi. HBV Vertical

Transmission: The Real Life. Oral Presentation. Israeli Association for the Study

of Liver, Eilat, June 2014.

48. Yaari Shaul, Merhav Hadar, Khalaileh Abd, Rowe Mena, Daher Saleh, Safadi

Rifaat. Telaprevir or Boceprevir-based triple therapy for HCV in liver transplanted

patients. Oral Presentation. Israeli Association for the Study of Liver, Eilat, June

2014.

49. Rifaat Safadi. The Role of NLG4 between Insulin Resistance and Innate Immunity

in Fatty Liver Disease. The First World Conference on Targeting Liver Diseases.

June, 2014, Jerusalem, Israel.

50. Villenchik R, Shteyer R, Mahamid M, Nator N, Safadi R. Advanced liver disease

correlates with low serum lysosomal acid lipase activity. ORAL ePoster, EASL

annual meeting, Vienna, The International Liver Congress™ 2015.

51. Amer J, Salhab A, Safadi R. Pioglitazone hydrochloride prevents nk cell insulin

resistance and enhances their activity in nonalcoholic fatty liver disease patients via

mtor pathway. ORAL ePoster, EASL annual meeting, Vienna, The International

Liver Congress™ 2015.

52. Amer J, Salhab A, Safadi R. Pioglitazone hydrochloride prevents NK cell insulin

resistance and enhances their activity in nonalcoholic fatty liver disease patients via

mTOR pathway. ORAL ePoster, EASL annual meeting, Vienna, The International

Liver Congress™ 2015.

53. Johnny Amer, Ahmad Salhab, Rifaat Safadi. Recombinant b-neuroxin inhibited

expressions of neuroligin-4 (NLG4) receptor and enhanced in vitro killing of NK

cells involving IL-4 pathway. ORAL at The Israeli Association for the Study of

Liver, Eilat, June 2015.

54. Johnny Amer, Ahmad Salhab, Rifaat Safadi. Recombinant neuroligin 4 (NLG4)

activates NK cells and attenuate fibrogenesis in Nonalcoholic Fatty liver Disease.

ORAL at The Israeli Association for the Study of Liver, Eilat, June 2015.

55. Nidaa Natour, Yusef Azraq, Muhamad Adila, Liat Appelbaum, Izhar Levi, Rifaat

Safadi. The Natural History of Ultrasound diagnosed nonalcoholic fatty liver

disease (NAFLD) in Hadassah: Long-term mortality. ORAL at The Israeli

Association for the Study of Liver, Eilat, June 2015.


, 2017

44

56. Shaul Yaari, Orit Pappo, Salech Daher, Ari Benson, Nadav Ilani, Tova Goldberg,

Mohamad Masarowah, Rifaat Safadi. HCV fibrosis progression in Hadassah by Re

Biopsies: Suggestion how to monitor low fibrotics. ORAL at The Israeli


57. Johnny Amer, Ahmad Salhab, Rifaat Safadi. Pioglitazone hydrochloride prevents

NK cell insulin resistance and enhances their activity in nonalcoholic fatty liver

disease patients via mtor pathway. ORAL at The Israeli Association for the Study

of Liver, Eilat, June 2015.

58. Abed Khalaileh, Izhar Levi, Oded Cohen-Arazi, Tova Nesher, Allan Bloom, Jacob

Sosna, Liat Appelbaum, Alexander Klimov, Hadar Merhav, Rifaat Safadi. The

effect of bridging Therapy on Liver Transplantation outcome for HCC, Hadassah

Experience. Oral Presentation at the Annual Meeting of the Israel Transplantation

Society, October 2015.

59. Abed Khalaileh, Mohamad Masarowah, Mina Rowe, Hadar Merhav, Rifaat Safadi.

Direct-Acting Antivirals for recurrent HCV infection following liver

transplantation: Real Life Hadassah experience. Oral Presentation at the Annual

Meeting of the Israel Transplantation Society, October 2015.

60. Ahmad Salhab, Johnny Amer, Rifaat Safadi. Liver NK cells from NLG4-/- mice

inhibit progressions of hepatocellular carcinoma of C57BL/6 mice model through

decrease in p53 and Akt expressions. Oral presentation, The European Association

for the Study of the Liver (EASL) HCC Summit, Geneva, February 2016.


, 2017

45

Poster Presentations:

1. Zylber-Katz E, Safadi R, Levy I, Caraco Y. Digoxin-specific FAB fragments in the

treatment of oleander poisoning in man.Therapeutic Drug Monitoring 17:419, 1995.

4th

International Congress of Therapeutic Drug Monitoring and Clinical Toxicology.

September 1995, Vienna, Austria.

2. Zimmerman J, Shouhat V, Tsvang E, Wengrower D, Safadi R. Predictors of

Mortality in Patients Aged > 80 Years Admitted to Hospital For Upper

Gastrointestinal Hemorrhage. American Society for Gastrointestinal Endoscopy

Annual Meeting, May 19-22, 1996.

3. Zimmerman J, Tsvang E, Wengrower D, Shouhat V, Safadi R. Upper

Gastrointestinal Hemorrhage (UGIH) In The Elderly: Distinct Clinical Features.

American Society for Gastrointestinal Endoscopy Annual Meeting, 43:363; 1996.

4. Safadi R, Shouval D, Ilan Y, Ashur Y, Eid A, Jurim U, Livni N, Galun E. Absence

of Correlation Between Increased HCV Viremia Following Liver Transplantation

and Clinical Coarse of Re-Infection. European Association For The Study of The

Liver, August 26-29, Journal of Hepatology, Supplement, 1: 148, 1996.

5. Haviv Y, Popovtzer MM, Silver J, Rubinger D, Gutman A, Gare M, Safadi R.

Fanconi’s syndrome (FS) induced by maleic acid analogue therapy: evidence for

renal tubular mitochondrial damage. Amer Soc of Nephrology, November 3-6, 1996.

6. Zimmerman J, Jonas T, Arnon R, Tsvang E, Safadi R, Wengrower D. Upper

Gastrointestinal (UGI) Hemorrhage In Cancer Patients: Etiology and Prognosis.

American Society for Gastrointestinal Endoscopy Annual Meeting. May, 1997.


Long term hepatitis B virus immunoglobulin therapy for HBV re infection following

liver transplantation. American Society of Transplantation Surgeons, 1997.

8. Pappo O, Livni N, Eid A, Friedlander M, Backenroth R, Safadi R, Shouval D, and

Galun E. Increased hepatocyte TGF expression is associated with fibrosing

cholestatic hepatitis in kidney transplant patients. Regulation of Liver Gene

Expression In Health & Disease: 121, 1997.

9. Schaap T, Eideiman L.A, Safadi R, Zelig O, Eid A, Jurim O, Rund D, Manny N,

Shouval D, Rachmilevitz E. Plasma exchange in operating room during liver

transplantation. 11th

Congress of European Society for Haemapheresis, 7th

Congress

of French Society for Haemapheresis. Dijon, France - September 14 -17, 1997.


, 2017

46

10. Pappo O, Backenroth R, Eid A, Jurim O, Friedlander M, Safadi R, Livni N, Daudi

N, and Galun E. Fibrosing cholestatic hepatitis in kidney transplant patients with

HCV infection. Israel Association For The Study Of The Liver, 1998.

11. Safadi R, Shouval D, Ilan Y, Ashur Y, Eid A, Jurim U, Livni N, Galun E. Aplastic

Anemia- Associated Hepatitis successfully treated by Bone Marrow Transplantation.

European Association For The Study of The Liver, August 26-29, Journal of

Hepatology, Supplement, 1: 190, 1998.

12. Safadi R, Ilan Y, Galun E, Shouval D. Fulminant Hepatitis A and liver

transplantation. AASLD, Chicago 1998.

13. Ashur Y, Ilan Y, Galun E, Safadi R, Shouval D and Tur-Kaspa R. Long term

beneficial effect of alpha Interferon in patients bearing hepatitis B precore mutant.

European Association For The Study of The Liver, Journal of Hepatology,

Supplement No. 1, 30: 257, 1999.

14. Safadi R, Kogan J, Ilan Y, Ashur Y, Galunn E, Abo-Much S and Shouval D.

Fulminant Hepatitis B: Follow-up and prognosis. European Association For The

Study of The Liver, Journal of Hepatology, Supplement No. 1, 30: 257, 1999.

15. Gotsman I, Beinart R, Safadi R, Rabani E, Engelhard D, Shouval D, Gorecki M,

and Ilan Y. Oral tolerance towards Hepatitis B antigens in a murine model.

Digestive Disease Week, AGA, Orlando May-1999.

16. Safadi R, Ilan Y, Galun E, Shouval D. Fulminant Hepatitis and liver transplantation.

Digestive Disease Week, AGA, Orlando May-1999.

17. Israeli E, Ilan Y, Eid A, Adler R, Galun E, Ashur Y, and Safadi R. The course of

HBV following liver transplantation. Israel Transplantation Society, 1999.

18. Rudis R, Rudis E, Lupo Y, Safadi R and BonneO. Psychosocial model for

evaluation and intervention with candidates for organ transplantation. Israel


19. Induction of Oral Tolerance to Foreign Antigen (Ovalbumin) in Transgenic Mice

with Hepatocyte-specific Secretion of Interleukin-10 (IL-10). Rifaat Safadi, Jens

Brimnes, Lloyd Mayer, Masayuki Ohta, Francis Eng, Thomas Kraus, Wajahat Mehal

and Scott L Friedman. Poster, AASLD, Boston 2002.

20. Diminished Fibrosis and Altered Lymphocyte Subsets in Transgenic Mice with

Hepatocyte Overexpression of Interleukin-10. Rifaat Safadi, Masayuki Ohta, Carlos

E. Alvarez, Michael P. Cooreman, Francis Eng, Wajahat Mehal, Jonathan Bromberg


, 2017

47

and Scott L. Friedman. Poster, AASLD, Boston 2002.

21. Treatment of Chronic HBV infection via oral immune regulation: an increase of INF

gamma and a decrease of IL-10 mediated pathology. Eran Israeli, Rifaat Safadi,

Oren Shibolet, Aharon Bloch, Orit Pappo, Athalia Klien, Ruslana Alper, Mina

Rowe, Nila Hemed, Barbara Thalenfeid, Dean Engelhard, Elazar Rabbani and Yaron

Ilan. Abstract, AASLD, Boston 2002.

22. Clinical evaluation (phase II) of a mixture of two human monoclonal antibodies to

HBV in combination with Lamivudine: Safety and anti-viral properties. Eithan

Gallun, Rifaat Safadi, Norah Terrault, Emmet Keeffe, Palo Alto, Daniel Shouval,

Yaffa Ashur, Orit Pappo, Dov Terkieltaub, Merav Zohar, Yifat Zohar, Rachel Eren,

Shlomo Dagan. Abstract, AASLD, Boston 2002.

23. Late Cytomegalovirus infection occurring 3 or more years following liver

transplantation. Oren Shibolet, Yaron Ilan, Yosef Kalish, Rifaat Safadi, Yaffa

Ashur, Ahmed Eid, Daniel Shouval, Dana Wolf. Abstract, AASLD, Boston 2002.

24. Dagan S, Eren R, Graham N, Nussbaum O, Terkieltaub D, Terrault N, Tur-Kaspa R,

Lurie Y, Safadi R, Akerman Z, Galun E. Clinical evaluation of a human

monoclonal antibody against the envelope protein (E2) of HCV for prevention of

HCV infection. Poster, AASLD, Boston 2003.

25. Margalit M, Nagler A, Ohana M, Safadi R, Alper R, Sherman Y, Doviner V,

Rabbani E, Englehardt DL, Ilan Y. Adoptive transfer of NKT cells alleviates graft

versus host disease and improves survival in a murine model of semi-allogeneic

bone marrow transplantation: the role of the liver in tolerance induction. Poster,

AASLD, Boston 2003.

26. Galun E, Safadi R, Melhem A, Akerman Z, Ashur Y, Mathot I, Younossi ZM,

Minuk GY, Nussbaum O, Terkieltaub D, Graham N, Eren R, Dagan S. A phase 2

clinical study evaluating safety and efficacy of HEPEX-B, a mixture of two human

monoclonal antibodies to HBsAg in combination with Lamivudine in chronic HBV

patients. Abstract, AASLD, Boston 2003.

27. Higazi AAR, El Haj M, Melhem A, Horani A, Doron S, Alvarez CE, Friedman SL,

Ilan Y and Safadi R. Immune Modulator effects of Plasminogen Activators on

Hepatic Fibrogenesis. Poster, AASLD, Boston 2004.

28. Muhanna N, Bishra A, Doron S and Safadi R. Activated but not quiescent

lymphocytes undergo endocytosis inside activated Human hepatic stellate cells.


, 2017

48

Poster, AASLD, San Francisco, 2005.

29. Axelrod JH, Khvalevsky E, Doron S, Enk J, Melhem A, Nechemia Y, Pappo O, Haj

M, Galun E and Safadi R. Toll-like receptor 9 (TLR9) activation by CpG or pDNA

ameliorates hepatic fibrosis associated with lymphocyte alterations. Poster, AASLD,

Boston, 2006.



ameliorates hepatic fibrosis associated with lymphocyte alterations. Poster, AASLD,

Boston, 2007.

31. Michaeli R, Calderon R, Ashur Y, Safadi R. Vertical transmission of HBV in

Jerysalem at the vaccine era. Israeli Association for the Study of Liver, Eilat 2008.



ameliorates hepatic fibrosis associated with lymphocyte alterations. Oral

Presentation, EASL annual meeting, Milan, 2008.

33. Muhanna N, Doron S, Wald A, Horani A, Eid A, Pappo O, Friedman SL, Safadi R.

Activation of Hepatic Stellate Cells following Phagocytosis of Lymphocytes – a

Novel Pathway of Fibrogenesis. Poster, EASL annual meeting, Milan, 2008.

34. Muhanna N, Doron S, Horani A, Eid A, Safadi R. The Homeostasis Effects of

Hepatic Stellate Cells in Hepatocellular Carcinoma. Poster, EASL, Milan, 2008.

35. Muhanna N, Doron S, Horani A, Eid A, Safadi R. The Homeostasis Effects of

Hepatic Stellate Cells in Hepatocellular Carcinoma. Poster, EASL monothematic

HCC meeting, Prague, June, 2008.

36. Horani A, Shosayov D, Kerem E, Doron S , Ilan Y, Safad R. Alleviation of asthma

in a murine model is associated with intrahepatic NKT and CD4 lymphocyte

trapping: a potential role for the liver in the immune modulation of asthma. Poster,

European respiratory society – Berlin, October, 2008.

37. Horani A, Shosayov D, Kerem E, Doron S , Ilan Y, Safad R. Alleviation of asthma

in a murine model is associated with intrahepatic NKT and CD4 lymphocyte

trapping: a potential role for the liver in the immune modulation of asthma. Poster,

EASL Monothematic Conference in Liver Immunology – Hamburg, December,

2008.

38. Liaw Y, Chang T, Wu S, Schiff ER., Han K, Lai C, Safadi R, Lee S, Halota W,


, 2017

49

Goodman Z, Zhang H, Hindes R, Iloeje U, Kreter B, Beebe S. Long-term entecavir

therapy results in reversal of fibrosis/cirrhosis and continued histologic

improvement in patients with HBeAg(+) and (-) chronic hepatitis B: Results from

studies ETV-022, -027 and -901. Poster, AASLD, San Francisco, 2008.

39. Horani A, Shosayov D, Kerem E, Doron S , Ilan Y, Safad R. Immune alleviation of

Asthma model is modulated by hepatic entrapment of NKT cells associated with

liver injury. Poster, AASLD, San Francisco, 2008.

40. Ginsburg I, Koren E, Horani A, Doron S, Safadi R. Amelioration of hepatic fibrosis

via Triphala is associated with altered NKT lymphocytes. Poster, AASLD, San

Francisco, 2008.

41. Muhanna Nidal, Doron Sarit, Abu Tair Lina, Amer Johnny, Safadi Rifaat. The

pivotal role of hepatic stellate cells in hepatocellular carcinoma progression. Poster

Presentation, Bi-Annual meeting of the Israel Association for Gastroenterology and

Liver Diseases, Tel-Aviv, 2009.

42. Yun-Fan Liaw, Ting-Tsung Chang, Shun-Sheng Wu, Eugene R. Schiff, Kwang-

Hyub Han, Ching-Lung Lai, Rifaat Safadi, Samuel S. Lee, Waldemar Halota,

Zachary D. Goodman, Hui Zhang, Robert Hindes, Uchenna Iloeje, Suzanne Beebe,

Bruce Kreter. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis

and continued histologic improvement in patients with HBeAg(+) and (-) chronic

hepatitis B: Results from studies ETV-022, -027 and -901. ISVHLD, 2009.

43. Avraham Y, Alnadi H, Doron S, Amer J, Muhanna N, Abu-Tir L, Berry E.M,

Safadi R. CB2 cannabinoid receptors directly affect hepatic stellate cell activation

with lymphocyte alterations. Presidential Poster (Top 10%), AASLD, Boston,

2009.

44. Andreas Tromm, Ivan Bunganič, Eva Tomsová, Zsolt Tulassay, Milan Lukáš, Jan

Kykal, Marian Bátovský, Bohumil Fixa, Libor Gabalec, Rifaat Safadi, Heinz-

Jochen Kramm, István Altorjay, Hanns Löhr, Ioannis Koutroubakis, Simon Bar-

Meir, Davor Štimac, Ralf Mohrbacher, Roland Greinwald, and the International

Budenofalk Study Group. Both budesonide (9 mg) as well as high-dose Eudragit-L-

coated mesalamine (4.5 g) lead to high remission rates in moderately active Crohn’s

disease patients: A double-blind, double-dummy, randomized, multicenter study.

Digestive Disease Week of American Association of Gastroenterology, 2009

45. Rifaat Safadi, Qing Xie, Yagang Chen, You-Kuan Yin, Lai Wei, Seong Gyu


, 2017

50

Hwang, Eli Zuckerman, Ji-Dong Jia, Patricia Lopez. The Efficacy of Switching to

Telbivudine (LdT) In Chronic Hepatitis B (CHB) Patients Previously Treated with

Lamivudine (LAM). APASL, 2010.


Yael Nechemia, Orit Pappo, Eithan Galun & Rifaat Safadi . Pivotal effects of Toll-

like receptor-9 activation in hepatic fibrosis. Poster. Israel Gastroenterological

Association, Tel-Aviv 22/6/2010.

47. Yosefa Avraham, Lina Abu-Tair, Sarit Doron, Johnny Amer, Nidal Muhanna, Elliot

M. Berry, Rifaat Safadi. CB2 cannabinoid receptors directly affect hepatic stellate

cell activation with lymphocyte alterations: Pivotal Effects. EASL Signaling

Monothematic Conference, Amsterdam, 2010.

48. Nidal Muhanna, Sarit Doron, Lina Abu Tair, Johnny Amer, Rifaat Safadi. The

pivotal role of hepatic stellate cells in the in vivo and in vitro hepatocellular

carcinoma model. EASL Signaling Monothematic Conference, Amsterdam, 2010.

49. Johnny Amer, Mamoun Abdel-Nabi, Lina Abu Tair, Sarit Doron, Nidal Muhanna,

Avraham Abu-Tbol, Rifaat Safadi. The immune modulator role of Leptin &

Adiponectin in hepatic fibrosis via HSC phagocytosis of lymphocytes. EASL

Signaling Monothematic Conference, Amsterdam, 2010.

50. Johnny Amer, Sarit Doron, Lina Abu Tair, Rifaat Safadi. Differentiation of hepatic-

stellate-cells to 4 sub-populations following phagocytosis of lymphocytes: “A novel

non-invasive tool for fibrosis-scoring”. EASL Signaling Monothematic Conference,

Amsterdam, 2010.


Yael Nechemia, Orit Pappo, Eithan Galun, & Rifaat Safadi. Pivotal effects of Toll-

like receptor-9 activation in hepatic fibrosis. EASL Signaling Monothematic

Conference, Amsterdam, 2010.

52. Nidal Muhanna, Sarit Doron, Lina Abu Tair, Johnny Amer, Rifaat Safadi. The

pivotal role of hepatic stellate cells in the in vivo and in vitro hepatocellular

carcinoma model. EASL HCC Monothematic Conference, Croatia, 2010.

53. Nidal Muhanna, Sarit Doron, Lina Abu Tair, Johnny Amer, Safadi R. The pivotal

role of hepatic stellate cells in the in vivo & in vitro hepatocellular carcinoma

model. Poster, EASL annual meeting, Vienna, 2010.

54. K. Abed, L. Abu Tair, J. Amer, S. Doron, Muhanna N, R. Safadi. Adoptive-transfer


, 2017

51

of liver injury and regeneration using Parabiosis-system. Poster, EASL annual

meeting, Vienna, 2010.

55. K. Abed, L. Abu Tair, J. Amer, S. Doron, Muhanna N, R. Safadi. Lymphocytes

attenuate fibrogenic toxicity of bile acids; using in-vitro and in-vivo Parabiosis mice

system. Presidential Poster (Top 10%), AASLD, Boston, 2010.

56. S. Pianko, Y. Lurie, Y. Baruch, B. Leggett, B. Hughes, D. Shouval, D. Crawford, S.

Bell, J. George, R. Safadi, L. Mollison, S. Roberts, G. Feutren, M. Subramanian,

and the ACHIEVE-1 Investigators Team. Final results of ACHIEVE-1: albinterferon

alfa-2b plus ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis

C. APASL, 2010.

57. W.L. Chuang, C.M. Lee, S. Thongsawat, M. Cho, C.-Y. Peng, G. Shanmuganathan,

J. George, I.-S. Sheen, R. Safadi, S. Shah, T. Tanwandee, V. Malachai, S. Pianko,

H.-T. Kuo, C. Pramoolsinsap, G. Feutren, M. Subramanian, and the ACHIEVE-2/3

Investigators Team. Final results of ACHIEVE-2/3: albinterferon alfa-2b plus

ribavirin in treatment-naïve patients with genotype 2/3 chronic hepatitis C. APASL,

2010.


58. Johnny Amer, Nidal Muhanna, Sarit Doron, Lina Abu-Tair, Rifaat Safadi. A novel

non-invasive tool for fibrosis-scoring via phagocytosis of lymphocytes. Poster,

EASL Monothematic Conference, Nice 2011.

59. George Haviv, Mahmod Mahamid, Rifaat Safadi. Hepatitis B Virus replication

following intra articulat Methylprednisolone Acetate injection at the osteoarthritic

knee in HBsAg carrier patients. Poster, EULAR, London 2011.

60. Johnny Amer, Rami Grifat, Lina Abu-Tair, Sarit Doron, Rifaat Safadi. The natural

course of Hepatic Fibrosis mice model during pregnancy. Poster, EASL annual

meeting, Berlin, 2011.

61. Johnny Amer, Lina Abu Tair, Mahmud Mahamid, Sarit Doron, Rifaat Safadi.

HCV-lymphocytes differentiate Hepatic Stellate Cells to 4 sub-populations and may

provide a novel in-vitro Flow-Cytometric tool for fibrosis scoring. Poster, EASL

annual meeting, Berlin, 2011.

62. Nidal Muhanna, Sarit Doron, Johnny Amer, Jean-Yves Siche, Rifaat Safadi. The

immune interplay between thyroid papillary carcinoma and hepatic fibrosis. Poster,

Israeli ENT Conference. Eilat, 2011.


, 2017

52

63. Lina Abu-Tair, Johnny Amer, Sarit Doron, Nidal Muhanna, Rifaat Safadi. The

immune modulatory effects of leptin & adiponectin in hepatic fibrosis via HSC

phagocytosis of lymphocytes. Poster, EASL Monothematic Conference "Liver

Fibrogenesis: Common and Organ Specific Mechanisms" Petersberg, June 17-18,

2011.

64. Nidal Muhanna, Sarit Doron, Johnny Amer, Jean-Yves Siche, Rifaat Safadi. The

immune interplay between thyroid papillary carcinoma and hepatic fibrosis. Poster,

EASL Monothematic Conference "Liver Fibrogenesis: Common and Organ Specific

Mechanisms" Petersberg, June 17-18, 2011.

65. Johnny Amer, Lina Abu Tair, Mahmud Mahamid, Sarit Doron, Rifaat Safadi. A

novel flow-cytometric tool for fibrosis-scoring through hepatic-stellate-cells

differentiation to 4 sub-populations. Poster, EASL Monothematic Conference

"Liver Fibrogenesis: Common and Organ Specific Mechanisms" Petersberg, June

17-18, 2011.

66. Lina Abu-Tair, Sarit Doron, Johnny Amer, Mahmoud Mahamid, Saif Abu-Mouch,

Rifaat Safadi. The anti-fibrotic immune effects of 25-Hydroxy-vitamin-D in HCV

and mice fibrosis model. Poster, EASL Monothematic Conference "Liver

Fibrogenesis: Common and Organ Specific Mechanisms" Petersberg, June 17-18,

2011.

67. Johnny Amer, Rami Grifat, Lina Abu-Tair, Sarit Doron, Rufayda Mruwat, Carmel

Kasher, Areej El-Khatib, Rifaat Safadi. The pro-fibrotic effects of pregnancy in a

hepatic fibrosis mice model. Poster, AASLD, San Francisco, 2011.

68. Amal Bishara, Ola Haj-Yehya-Abu-Aita, Johnny Amer & Rifaat Safadi. HLA-C

matching with liver transplantation outcome suggest NK role via HLA-Cw*

alloantigen. Poster, EASL annual meeting, Barcelona, 2012.

69. Mahamid Mahmud, Ibrahim Abdullah, Rami Ghantous, Johnny Amer, Sarit Doron

and Rifaat Safadi. Low Vitamin D levels in Nonalcoholic Fatty Liver Disease

associate with Insulin resistance and Liver Injury progression via immune NK

mechanism. Poster, EASL annual meeting, Barcelona, 2012.

70. R. Safadi, FM. Konikoff, R. Oren, T. Gilat and the Aramchol's Israeli Research

Group*. A PHASE-2, RANDOMIZED, DOUBLE BLIND, PLACEBO-

CONTROLLED TRIAL OF ARAMCHOL FOR THE TREATMENT OF NON

ALCOHOLIC FATTY LIVER DISEASE (NAFLD). Poster, EASL annual meeting,


, 2017

53

Barcelona, 2012.

71. Johnny Amer, Lina Abu Tair, Sarit Doron and Rifaat Safadi. HCV-lymphocytes

differentiate hepatic-stellate-cells to 4 sub-populations and may provide a novel in-

vitro flow-cytometric tool for fibrosis-scoring. Poster, EASL monothmatic meeting,

Prague, 2012.

72. Mina Rowe, Ahmad Eid, Yemima Lupo, Keren Balut, Hadar Merhav and Rifaat

Safadi. PSYCHOSOCIAL EVALUATION OF CANDIDATES FOR LIVER

TRANSPLANTATION PREDICTS POST TRANSPLANTATON OUTCOME

Poster, EASL annual meeting, Amsterdam, 2013.

73. Sarit Doron, Lior Lupu, Lina Abu-Tair, Johnny Amer, Rifaat Safadi. Increased

Neuroligin-4 receptor expressions in NK cells are associated with impair killing

activity in leptin-deficient mice (ob/ob). Poster, EASL annual meeting,

Amsterdam, 2013.

74. Johnny Amer, Mahamid N. Mahmud, Lina Abu-Tair, Sarit Doron, Rami Ghantous,

Rifaat Safadi. NLGn4 and NMDA receptors mediate NK cell activity via mTOR

pathway in NAFLD. Poster, EASL annual meeting, Amsterdam, 2013.

75. Lina Abu-Tair, Sarit Doron, Johnny Amer, Rifaat Safadi. Neuroligin-4 receptor

silencing increase human Natural Killer activity and decreased hepatic stellate cells

activation. Poster, EASL annual meeting, Amsterdam, 2013.

76. Johnny Amer, Mahmud Mahamid, Lina Abu-Tair, Sarit Doron, Rami Ghantous,

Rifaat Safadi. Elevated levels of Serum Alanine affect NK function and Predict

Severity of Liver Fibrosis in NAFLD patients. Poster, AASLD annual meeting,

Washnighton, 2013.

77. Johnny Amer, Hashem Bsaso, Mahmud Mahamid, Lina Abu-Tair, Sarit Doron,

Rami Ghantous, Rifaat Safadi. Increased Levels of Serum Alanine Impair NK

Function and Predict Severity of Liver Fibrosis in NAFLD patients. Poster, EASL

annual meeting, London, 2014.

78. Johnny Amer, Mahamid N. Mahmud, Lina Abu-Tair, Sarit Doron, Rami Ghantous,

Rifaat Safadi. Insulin resistance in NK cells from F4-fibrosis inhibit mTOR

expressions and are associated with decreased F-actin and killing ability in NASH

patients. Poster, EASL annual meeting, London, 2014.

79. Gane E.J, Lai C.-L, Xie Q, Liaw Y.F, Thongsawat S, Chan H.L.Y, Wang Y, S.G

Hwang, Safadi R, Jung M, Uddin A, Janssens N, Trylesinski A.Evaluation of


, 2017

54

estimated glomerular filtration rate during continuous 4-year treatment with

Telbivudine in patients with bridging fibrosis / cirrhosis. Poster, EASL annual

meeting, London, 2014.

80. Budesonide in Granulomatous Hepatitis. Oral Presentation. Israeli Association for

the Study of Liver, Eilat, June 2014.

81. Johnny Amer, Sarit Doron, Ahmad Salhab, Nadav Ilani, Rifaat Safadi.

Homozygous NLG4-/-

(KO) mice showed a decreased inflammatory and fibrotic

profile and is associated with NK cells increased killing activity. Poster, Israeli


82. Johnny Amer, Hashem Bsaso, Mahmud Mahamid, Lina Abu-Tair, Sarit Doron,

Rami Ghantous, Rifaat Safadi. Increased Levels of Serum Alanine Impair NK

Function and Predict Severity of Liver Fibrosis in NAFLD patients. Poster, Israeli


83. Johnny Amer, Sarit Doron, Ahmad Salhab, Rifaat Safadi. Homozygous NLG4-/-

(KO) mice showed chronic oxidative stress with reduced respiratory burst response

of liver lymphocytes. Poster, Israeli Association for the Study of Liver, Eilat, June

2014.

84. Johnny Amer, Sarit Doron, Ahmad Salhab, Rifaat Safadi. Insulin resistance of

CD56dim

NK cells decrease NK killing ability in NASH patients with advanced

fibrosis. Presidential Poster of Distinction at The Liver Meeting®, AASLD's 65

th

Annual Meeting in Boston, Massachusetts, November, 2014. This poster was in the

top 10% of all abstracts selected for poster presentation.

85. Johnny Amer, Sarit Doron, Ahmad Salhab, Rifaat Safadi. Liver lymphocytes from

NLG4-/-

(KO) mice showed chronic oxidative stress with reduced respiratory burst

response. Poster at The Liver Meeting®, AASLD's 65

th Annual Meeting in Boston,

Massachusetts, November, 2014.

86. Abed Khalaileh, Izhar Levi, Oded Cohen-Arazi, Tova Nesher, Allan Bloom, Jacob

Sosna, Liat Appelbaum, Alexander Klimov, Hadar Merhav, Rifaat Safadi. The

effect of bridging Therapy on Liver Transplantation outcome for HCC, Hadassah

Experience. EP05A-053, ePOSTER at the 2016 IHPBA World Congress, São

Paulo, Brazil, April 20-23, 2016.

87. Benson Ariel, Mina Rowe, Ahmad Eid, Keren Balut, Hadar Merhav, Khalaila Abed

and Rifaat Safadi. Psychosocial Evaluation Of Candidates For Liver


, 2017

55

Transplantation Predicts Post Transplantaton Outcome. EP05A-013, ePOSTER at

the 2016 IHPBA World Congress, São Paulo, Brazil, April 20-23, 2016.

88. Villenchik R, Shteyer R, Mahamid M, Nator N, Safadi R. Advanced liver disease

correlates with low serum lysosomal acid lipase activity. Poster at The Israeli


89. Salech Salech Daher, Shaul Yaari, Ariel Benson, Nadav Ilani, Goldberg Tova,

Mohamad Masarowah, and Rifaat Safadi. The Distribution, alterations & changing

of HCV Genotype. Poster at the Israeli Association for the Study of Liver, Eilat,

June 2015.

90. Shaul Yaari, Orit Pappo, Salech Daher, Ariel Benson, Nadav Ilani, Tova Goldberg,

Mohamad Masarowah, Johnny Amer and Rifaat Safadi. Repeated biopsies within

23 years showed increased frequency of HCV infections & suggested a 3-year

median monitoring to allocate fibrosis progressions. ePoster 1878 at The Liver

Meeting®, AASLD's 66

th Annual Meeting in Boston, San Francisco, November,

2015.

91. Johnny Amer, Ahmad Salhab & Rifaat Safadi. Liver NK cells from NLG4-/-

mice

inhibit progressions of hepatocellular carcinoma of C57BL/6 mice model through

decrease in p53 & Akt expressions. ePoster 1532 at The Liver Meeting®, AASLD's

66th

Annual Meeting in Boston, San Francisco, November, 2015.

92. Johnny Amer, Ahmad Salhab & Rifaat Safadi. NK cells from homozygous NLG4-/-

(KO) mice showed increased in their killing activity through PI3K/AKT/mTOR

pathway and decreased interleukin-4. ePoster 660 at The Liver Meeting®, AASLD's

66th

Annual Meeting in Boston, San Francisco, November, 2015

93. Johnny Amer, Ahmad Salhab, Rifaat Safadi. CD49a- CD49b+ NK1.1 cells in

C57/BL fibrotic livers are distinct from peripheral NK cells in their

CD107a/neurologin4 activatory marker. Poster, EASL annual meeting, Barcelona,

2016.

94. Johnny Amer, Ahmad Salhab, Rifaat Safadi. Modulations in vitamin D receptor

(VDR) expressions in late fibrosis model of Balb/c mice inhibited 25-Hydroxy-

vitamin-D3 alleviation of liver NK cytotoxicity. Poster, EASL annual meeting,

Barcelona, 2016.

95. Johnny Amer, Ahmad Salhab, Rifaat Safadi. Recombinant β-neuroxin as a

therapeutic target to inhibit fibrosis through alleviation in NK cells cytotoxicity


, 2017

56

following inhibition of Neuroligin-4 (NLG4) receptor. ePoster, EASL

Monothematic Conference: “Liver Fibrosis: the next goal of targeted therapy?”, 17-

18 June 2016, Porto, Portugal.

96. Johnny Amer, Ahmad Salhab, Rifaat Safadi. NK cells from homozygous NLG4-/-

(ko) mice inhibit liver fibrosis through PI3k/AKT/mTOR pathway and decreased

Interleukin-4. ePoster, EASL Monothematic Conference: “Liver Fibrosis: the next

goal of targeted therapy?”, 17-18 June 2016, Porto, Portugal.

97. Johnny Amer, Ahmad Salhab, Rifaat Safadi. 25(OH) D3 alleviate liver NK

cytotoxicity in early but not in late fibrosis model of BALB/c mice due to

modulations in vitamin D receptor. ePoster, EASL Monothematic Conference:

“Liver Fibrosis: the next goal of targeted therapy?”, 17-18 June 2016, Porto,

Portugal.

98. Ahmad Salhab, Johnny Amer & Rifaat Safadi. 25(OH) D3 alleviate liver NK

cytotoxicity in early but not in late fibrosis model of Balb/c mice due to

modulations in vitamin D receptor. Poster at The Liver Meeting®, AASLD's 67

th

Annual Meeting in Boston, San Francisco, November, 2016

99. Ahmad Salhab, Johnny Amer & Rifaat Safadi. Reduced PI3K pathway in NK cells

of F4-NAFLD patients inhibited mTOR expressions and was correlated with their

impaired function. Poster at The Liver Meeting®, AASLD's 67

th Annual Meeting in

Boston, San Francisco, November, 2016.

100. Johnny Amer, Ahmad Salhab, Harbi Khalieleh, Rifaat Safadi. Neuroligin4 over

expression on NK cells cause their impairment in patients with cirrhosis and HCC.

ePoster, the European Association for the Study of the Liver (EASL) HCC Summit,

Geneva, February 2016.

101. Johnny Amer, Ahmad Salhab, Rajiv Jalan, Rifaat Safadi. Ammonia elevates B-

neurexin in hepatic stellate cells to escape NK cells activity. ePoster & Paper

Poster Presentation, the European Association for the Study of the Liver (EASL)

annual meeting, Amsterdam, 2017.

102. Johnny Amer, Ahmad Salhab, Harbi Khalieleh, Rifaat Safadi. Neuroligin4 over

expression on NK cells cause their impairment in patients with cirrhosis and HCC.

ePoster & Paper Poster Presentation, the European Association for the Study of

the Liver (EASL) annual meeting, Amsterdam, 2017.

103. Tannous Kuszum, Rifaat Safadi. Occult Advanced Fibrosis in the General


, 2017

57

Population. ePoster & Paper Poster Presentation, the European Association for

the Study of the Liver (EASL) annual meeting, Amsterdam, 2017.


, 2017

58

Scientific Biography (14/8/2016)

Basic science: Immune modulation of hepatic fibrosis:

Past goals:

Hepatic fibrosis and fibrosis progression to cirrhosis are the end outcome of chronic

liver injury from any etiology. Activation of hepatic stellate cells (HSCs), as a main

resource for hepatic myofibroblasts, is the key pathway for hepatic fibrosis. I started my

research in the fibrogenesis of liver injury within my visiting scholar at the Mount Sinai

School of Medicine, NY from 2001-2002 with Prof. Scott L Friedman. Since end of

2002, I have established a new laboratory in Hadassah, Jerusalem for hepatic fibrosis

research and working independently to explore the field. My research is the first to

define a role of lymphocytes in activating or killing of HSCs. Therefore, I could define

which lymphocyte subsets are pro and which are anti fibrotic and how? My generated

results and publications opened a new niche & new Hypothesis driven research for

"immune modulation of hepatic fibrosis". This niche was very un-explored and becames

so popular recently worldwide, as other groups joined this scientific field with ongoing

generation of newly important knowledge. Our results are also regenerated and

published by others, including another NIH group (Radaeva S, et. al. Gastroenterology.

2006;130:435). Part of those researchers actually have had regenerated similar data to

ours; suggesting the reality of findings. In NY, we defined the CD8 subsets as pro

fibrotic lymphocytes that can directly activate hepatic fibrosis (see Original Papers in

Peer Reviewed Journals, manuscript#46 including editorial and #39). Thereafter, in

Hadassah I showed that NK cells had anti fibrotic properties. Since then, my laboratory

is investigating since then how the lymphocyte/ HSCs interplay is working and how it is

affected. We observed that the interaction between HSCs and lymphocytes mediated by

a direct proximity and adhesion (#30) that ends up as phagocytosis of lymphocytes by

the HSC (#28) both in rodent and human fibrosis.

CXCL12/CXCR4 pathway was involved in advanced liver disease that is

associated with HCV or HBV (Original Papers in Peer Reviewed Journals,

manuscript#44). Toll Like Receptor 9 (TLR9) found to mediate opposite effects via

CpG, it is directly proliferating HSCs towards fibrogenesis but also proliferating NK

cells towards anti fibrotic outcome (Original Papers in Peer Reviewed Journals,

manuscript#10). Plasminogen activators affect fibrosis in part by liver-specific


, 2017

59

activation of CD8 subsets that govern the fibrogenic activity of HSC (Original Papers in

Peer Reviewed Journals, manuscript#27). CB2 receptors are also involved (Original

Papers in Peer Reviewed Journals, manuscript#13). Leptin enhances HSCs activation

both directly and through HCV-lymphocytes proliferation and phagocytosis. Leptin

contribute to lymphocyte proliferative activation in a Th2 manner and decrease their

apoptosis. In animal model, leptin receptor of the splenocytes and not of HSCs mediated

phagocytosis. (Original Papers in Peer Reviewed Journals, manuscript#16).

Among others, Copaxone had a significant anti-fibrotic effect following CCl4

administration through lymphocytes alterations (#33). Herbal P-Liver attenuates hepatic

fibrogenesis via lymphocyte alterations (Original Papers in Peer Reviewed Journals,

manuscript#25) and even attenuated asthma animal model via liver lymphocytes

alterations (Original Papers in Peer Reviewed Journals, manuscript#14 & 24).

Present achievements:

Recently, we are focusing specifically in the NK cell biology and its role in hepatic

fibrogenesis. We found that the vitamin D can activate NK cells and increased the anti

fibrotic activity via the HSC killing. (Posters & Oral Presentations #18, 22, 23, 34). We

evaluate the anti-fibrotic activity of iKIR (Inhibitory-killing-immunoglobulin-related-

receptors) scilencing by siRNAs in liver-injury using human in-vitro and mice in vivo

models. iKIR siRNA transfected lymphocytes showed lower fibrogenic effect both in

vivo and in vitro (Original Papers in Peer Reviewed Journals, manuscript#23). However,

NK cells lost the killing effects in the advanced fibrosis and cirrhosis. Therefore, we did

a gene array analysis of the isolated peripheral blood NK cells from healthy controls and

from cirrhotic patient of different etiologies. Among others, we found an overexpression

of the Neurolgin-4 (NLG4, known as a postsynaptic neurologic receptor associated with

Autism) in the cirrhotic NK cells. Increased NK cell related NLG4 expressions in

cirrhosis (non Alcoholic Fatty Liver Disease, NAFLD) was associated with decrease of

the killing marker CD107a and Insulin Receptor expressions, but with increased

expressions of the scaffolding proteins (PSD95, f-Actin and the nMDR) in an mTOR-

mediated pathway. This NLG4 & nMDR pathway was interactive with plasma

stimulators such like Alanine (that found higher in increased fibrosis), Glutamine and

tPA to reduce NK killing, suggesting them as a system that regulating killing of NK

cells via metabolic effects in the metabolic syndrome. NLG4 knockdown by siRNA


, 2017

60

increased the killing ability both by markers and by functional killing of NK cells.

Similar results were also generated in animal mice model of NLG4-/-

and opposite

results in the Ob/Ob obese animal model of NAFLD. Therefore, it is concluding that

NLG4 in NK cells suggested mediating an inhibitory signaling of killing via scaffolding

proteins in an mTOR dependent pathway. The NLG4 & nMDR system are interacting

directly with metabolic changes in metabolic syndrome and contribute to impair killing

that is contributing for fibrosis progression to cirrhosis and even cancer.

Future goals:

We started a KAMIN project to produce anti-NLG4 monoclonal antibodies for

therapeutic use in the field of fatty liver disease and cancer. This is a 3 years project

started by end of 2015. This grant was interrupted August 2016 due to agreement with

PHARMA, see bellow links:

http://www.pressreleasepoint.com/biolinerx-announces-licensing-liver-fibrosis-project-

under-strategic-collaboration

https://www.thestreet.com/story/13658762/1/biolinerx-announces-in-licensing-of-liver-

fibrosis-project-under-strategic-collaboration.html

http://www.smarteranalyst.com/2016/08/01/company-update-nasdaqblrx-bioline-rx-ltd-

announces-licensing-liver-fibrosis-project-strategic-collaboration/

http://www.bioline.org.br/request?dv08147

http://www.bioline.org.br/request?oc09060

http://www.biolinerx.com/default.asp?pageid=16&itemid=450

http://m.sponser.co.il/article.php?id=71207

http://www.talniri.co.il/marketnews/article.asp?id=77918

http://www.funder.co.il/article.aspx?idx=69084

Many attempts are ongoing toward targeting liver diseases in genera, hepatic fibrosis

and fatty liver disease in particular:

PRESS RELEASE:

Novel drug candidate modulates immune system to reduce liver fibrosis in non-

alcoholic steatohepatitis

Tel Aviv, Israel – August 1, 2016 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a

clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and

http://www.pressreleasepoint.com/biolinerx-announces-licensing-liver-fibrosis-project-under-strategic-collaboration

http://www.pressreleasepoint.com/biolinerx-announces-licensing-liver-fibrosis-project-under-strategic-collaboration

https://www.thestreet.com/story/13658762/1/biolinerx-announces-in-licensing-of-liver-fibrosis-project-under-strategic-collaboration.html

https://www.thestreet.com/story/13658762/1/biolinerx-announces-in-licensing-of-liver-fibrosis-project-under-strategic-collaboration.html

http://www.smarteranalyst.com/2016/08/01/company-update-nasdaqblrx-bioline-rx-ltd-announces-licensing-liver-fibrosis-project-strategic-collaboration/

http://www.smarteranalyst.com/2016/08/01/company-update-nasdaqblrx-bioline-rx-ltd-announces-licensing-liver-fibrosis-project-strategic-collaboration/

http://www.bioline.org.br/request?dv08147

http://www.bioline.org.br/request?oc09060

http://www.biolinerx.com/default.asp?pageid=16&itemid=450

http://m.sponser.co.il/article.php?id=71207

http://www.talniri.co.il/marketnews/article.asp?id=77918

http://www.funder.co.il/article.aspx?idx=69084


, 2017

61

developing promising therapeutic candidates, announced today that it has signed an

exclusive worldwide agreement with Hadasit, the Technology Transfer Company of

Hadassah Medical Organization, for the in-licensing of a drug candidate for the

treatment of liver fibrosis, and in particular, non-alcoholic steatohepatitis (NASH). This

drug candidate, to be called BL-1210, is the first project to be in-licensed under the

framework of the Company’s strategic collaboration with Novartis Pharma AG for the

screening and development of novel drug candidates.

The newly in-licensed pre-clinical project, developed by Prof. Rifaat Safadi, Head of the

Liver Unit, Department of Medicine at Hadassah Medical Center, Jerusalem, Israel,

offers a novel mechanism for controlling liver fibrosis through modulation of the

immune system. BioLineRx will address the novel drug target that will modulate the

immune system to ultimately reduce the liver fibrogenesis and therefore reduce liver

scarring. Limiting the fibrosis process this way will potentially control the disease

progression.

"After jointly screening and evaluating a wide range of pre-clinical and clinical

therapeutic candidates, we are excited with the selection of this potential treatment for

non-alcoholic steatohepatitis to be developed as part of our multi-year partnership with

Novartis, especially since there are no approved treatments for this prevalent condition,”

explained Dr. Kinneret Savitsky, CEO of BioLineRx. "Under the collaboration, Novartis

will provide us with valuable professional advice and consultancy throughout the

development process. This project fits our strategic focus on the immunology space,

since it works through modulation of the immune system. Upon successful completion

of the feasibility stage, we plan to advance the project at full steam. We also expect to

bring additional promising projects to the collaboration by the end of the year.”

In December 2014, BioLineRx and Novartis Pharma AG entered into a multi-year

strategic collaboration to facilitate development and commercialization of Israeli-

sourced drug candidates. Leveraging BioLineRx’s close and long-lasting ties with

academic institutions, hospitals and biomedical companies in Israel, as well as its

proven project screening process and development expertise, Novartis will evaluate

projects identified and presented by BioLineRx for co-development and potential future


, 2017

62

licensing under the collaboration. The companies intend to co-develop a number of pre-

clinical and early clinical therapeutic projects through clinical proof-of-concept. As part

of the agreement, Novartis made an equity investment in BioLineRx of $10 million.

Clinical research:

Past goals:

I am a Principle Investigator in many (>85) different clinical studies since 2001.

However, my own clinical research (clinical observations, new treatments, vaccines and

preventions, and outcomes) mainly focused on viral hepatitis, nonalcoholic fatty liver

disease (NAFLD), liver transplantation (with HLA matching focus) as well as

inflammatory bowel diseases. Recently, a Phase-2 Randomized, Double blind, Placebo-

Controlled Trial of Aramchol for Non-Alcoholic Fatty Liver Disease was published

(Original Papers in Peer Reviewed Journals, manuscript#7). Aramchol therapy (fatty

acid-bile acid conjugate 3β-arachidyl-amido, 7α-12α-dihydroxy, 5β-cholan-24-oic acid)

was safe, tolerable, and significantly reduces liver fat content in patients with NAFLD.

Among others, I was the first one who studied Lamivudine therapy for prevention of

immunosuppressive-induced HBV reactivation in HBsAg carriers (Original Papers in

Peer Reviewed Journals #51). Then, I showed the efficacy of Switching to Telbivudine

in Chronic Hepatitis B Patients Previously Treated with Lamivudine (Original Papers in

Peer Reviewed Journals #22), it's efficacy in decompensated cirrhosis (Original Papers

in Peer Reviewed Journals #15) and safety Telbivudine plus pegylated interferon alfa-2a

(Original Papers in Peer Reviewed Journals #3).

Present achievements:

My recent thumb of print is improvement in Prevention of Perinatal hepatitis B

transmission. HBV vertical transmission is highly prevalent (Harefua 2013); in spite of

the universal vaccination program. In a prospective multicenter study, Sci-B-Vac is

superior to Engerix-B for preventing HBV vertical infection, probably due to effective

eradication. The threshold of infective maternal viral load was > 3 and not the reported 7

logs. Maternal antivirals are effective and should consider at the commonly accepted


, 2017

63

threshold as non-pregnant indication.

On the other hand, fatty liver disease becomes the elading etiology for chronic liver

disease with unmet need. A Phase-2 Randomized, Double blind, Placebo-Controlled

Trial of Aramchol for Non-Alcoholic Fatty Liver Disease showed a beneficial effect

(Original Papers in Peer Reviewed Journals #7).

Future goals:

The samples from HBV vertical transmission study will be evaluated for sequencing to

allocate escape mutants. This might be helpful for the design of next vaccine generation.

As to fatty liver disease, a database is within recording for the Hadassah experience.

Many clinical studies are actually running at different channels.

curriculum vitae prof. rifaat safadi m.d....4 prof. rifaat safadi m.d., february 12th, 2017 4 prizes...

Documents